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ABSTRACT 
Background and objectives: Patients with ankylosing spondylitis (AS) have 
an increased risk of bone loss with development of osteoporosis and vertebral 
fractures (VFs) but also spinal new bone formation with growth of bony 
spurs (syndesmophytes) between the vertebrae. Measurements of spinal bone 
mineral density (BMD) by the routine method dual-energy x-ray 
absorptiometry (DXA) in anteroposterior (AP) projection can be difficult to 
interpret due to the spinal new bone formation. The general aims of this 
thesis were to study the development of bone loss and new bone formation 
over 5 years in patients with AS and to assess factors associated with the 
changes.  
Methods: The studies included in this thesis are based on a cohort of patients 
with AS according to the modified New York criteria recruited from three 
rheumatology clinics in western Sweden. Patients completed the same 
protocol at baseline and at the 5-year follow-up with assessment of BMD 
with DXA at the hip (femoral neck, total hip), the spine (AP, lateral) and total 
radius and spinal radiographs for grading of AS related spinal alterations and 
VFs. A group of men were randomized in an age-adjusted algorithm to 
undergo high-resolution peripheral quantitative computed tomography 
(HRpQCT) at the ultra-distal radius and tibia for assessment of volumetric 
BMD (vBMD), cortical area and microarchitecture. Serum hepatocyte growth 
factor (s-HGF) was analyzed with enzyme-linked immunosorbent assay 
(ELISA) in the total cohort. 
Results: Over 5 years, there were significant decreases in femoral neck BMD 
and tibia vBMD. Decreases were associated with signs of inflammation. In 
contrast, BMD at the total hip and the spine AP and lateral projections 
 increased. Use of bisphosphonates was associated with increases in BMD at 
all measured sites except tibia. Use of tumor necrosis factor inhibitors (TNFi) 
was associated with increases in BMD at AP spine and tibia. Only three 
patients developed new VFs. AS related spinal alterations increased 
significantly with higher increases in men compared to women. New 
predictors identified for spinal radiographic progression were obesity in both 
sexes and use of bisphosphonates and impaired mobility in women. Among 
previously known predictors, baseline AS related spinal alterations was 
shared by sexes, whereas baseline elevated CRP and smoking were predictors 
in men. The biomarker s-HGF was identified as a novel independent 
predictor of spinal radiographic progression in men.  
Conclusion: The studies in this thesis suggest that the best site to assess bone 
loss in patients with longstanding AS is at the femoral neck and that 
inflammation has a negative impact on bone loss and development of AS 
related spinal alterations and thus is an important treatment target. The 
studies give further reasons to counsel the patients to stop smoking and to 
encourage obese patients to weight loss. Treatments with bisphosphonates 
and TNFi had a positive impact on BMD. Further studies are suggested 
regarding the role of bisphosphonates in relation to spinal radiographic 
progression and whether s-HGF can be useful as a predictor for spinal 
radiographic progression.  
Keywords: Ankylosing spondylitis, bone mineral density, spinal new bone 
formation, longitudinal cohort study 
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SAMMANFATTNING PÅ SVENSKA 
Bakgrund och syfte: Hos patienter med den kroniska, reumatiska sjukdomen 
ankyloserande spondylit (AS) kan två olika typer av skelettpåverkan 
förekomma. Dels har patienter med AS en ökad risk för benförlust med 
utveckling av osteoporos och kotfrakturer och dels en ökad risk för 
bennybildning i ryggen med tillväxt av överbroande förbeningar mellan 
kotorna, s.k. syndesmofyter. Standardmetoden för att mäta bentäthet (BMD) 
är dual-energy x-ray absorptiometry (DXA) och vid mätning av BMD i 
ryggen används normalt anteroposterior projektion (AP), dvs. rakt framifrån. 
Hos patienter med AS kan resultaten från mätning med denna projektion vara 
svårvärderade då förbeningen i ryggen kan ge ett falskt högt värde. De 
övergripande syftena med denna avhandling var att studera utvecklingen av 
benförlust och bennybildning över fem års tid hos patienter med AS och att 
undersöka vilka faktorer som hade samband med förändringarna.  
Metoder: Studierna som ingår i denna avhandling baseras på en kohort av 
patienter med AS som rekryterades från reumatologklinikerna på Sahlgrenska 
Universitetssjukhuset, Södra Älvsborgs sjukhus och Alingsås Lasarett. 
Patienterna genomgick samma undersökningar vid baslinjen och 
femårsuppföljningen med mätning av BMD med DXA i höften 
(lårbenshalsen och totala höften), ryggen (AP och lateral mätning från sidan) 
och underarmen (totala radius) samt röntgen av ryggen för gradering av 
förbeningar i ryggen och gradering av kotfrakturer. En andel av männen 
randomiserades till undersökning med högupplöst perifer kvantitativ 
datortomografi (HRpQCT) av underarm och underben för mätning av 
volymetrisk BMD, kortikal area och mikroarkitektur. I hela patientgruppen 
togs blodprover och nivån av hepatocyte growth factor i serum (s-HGF) 
analyserades med enzyme-linked immunosorbent assay (ELISA). 
Resultat: Över fem år minskade BMD signifikant i lårbenshalsen och 
underbenet. Dessa minskningar var associerade till tecken på inflammation. I 
totala höften och ryggen, både AP och lateral mätning, hade däremot BMD 
ökat. Användning av bisfosfonater var förenat med ökning av BMD på alla 
mätlokaler utom underbenet. Användning av läkemedel som hämmar 
cytokinet tumörnekrosfaktor alfa (TNF-α) var relaterat till ökning av BMD i 
ryggen (AP) och underbenet. Endast tre patienter utvecklade ny kotfraktur. 
Förbeningen i ryggen ökade signifikant mer uttalat hos männen jämfört med 
kvinnorna. Nya riskfaktorer som identifierades för utveckling av förbening i 
ryggen var obesitas för både män och kvinnor och användning av 
bisfosfonater och nedsatt rygg- och höftrörlighet vid baslinjen för kvinnorna. 
 Bland tidigare kända riskfaktorer för utveckling av förbening i ryggen var 
förekomst av förbening i ryggen vid baslinjen gemensam riskfaktor för både 
män och kvinnor medan högt CRP vid baslinjen och rökning predikterade 
förbening i ryggen hos männen i vår kohort. En högre nivå av biomarkören s-
HGF var en oberoende riskfaktor för ökad förbening i ryggen hos männen.  
Konklusion: Studierna i denna avhandling tyder på att bästa lokalen att mäta 
bentäthet hos patienter med långvarig AS är lårbenshalsen och att systemisk 
inflammation bidrar till en ökad benförlust och också utveckling av förbening 
i ryggen. Därmed är hämning av inflammation ett viktigt behandlingsmål. 
Studierna ger ytterligare anledning att råda patienterna till rökstopp, hjälpa 
dem med rökavvänjning samt att stötta patienter med obesitas till 
viktminskning. Behandling med TNF-hämmare och bisfosfonater hade en 
positiv effekt på bentätheten. Det behövs ytterligare studier för att klarlägga 
bisfosfonaternas roll när det gäller förbeningen i ryggen och om HGF kan 
vara användbar som prediktor för utveckling av förbening i ryggen.  
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1 ANKYLOSING SPONDYLITIS 
1.1 INTRODUCTION 
Ankylosing spondylitis (AS) is a chronic, inflammatory disease that mainly 
affects the axial skeleton. AS is the major subtype of the family of related 
diseases called spondyloarthritis (SpA) that share common clinical and 
genetic characteristics. Psoriatic arthritis (PsA), arthritis associated with 
inflammatory bowel disease (IBD), reactive arthritis (ReA) and 
undifferentiated SpA are also part of the SpA-family. Depending on the 
clinical manifestations that predominate, SpA can be classified as axial SpA 
with symptoms mainly from the spine and sacroiliac (SI) joints or as 
peripheral SpA with symptoms mainly from peripheral joints and entheses. 
[1] Axial SpA includes both patients with radiographic findings of sacroiliitis 
in the SI-joints (radiographic axial SpA or AS) and patients without 
radiographic sacroiliitis (non-radiographic axial SpA (nr-axial SpA)). [2] 
The name ankylosing spondylitis derives from the Greek word “ankylosis” 
meaning stiffness, “spondylos” meaning vertebra, and the suffix ”–itis” 
which denotes inflammation. Ankylosing spondylitis is also known as 
Bechterew´s disease. 
1.2 EPIDEMIOLOGY 
AS typically starts in the third decade of life with an average disease or 
symptom onset of 25 years. [3] Studies have estimated the ratio of man to 
woman with AS to approach 2-3:1. [4-6] The prevalence of the disease varies 
between ethnical populations and geographical regions, and correlates 
strongly to the prevalences of human leucocyte antigen (HLA) B27 
positivity. [7] The prevalence of HLA-B27 in blood donors in northern 
Sweden has been shown to be 16.6% [8], whereas the prevalence in southern 
Sweden was 10 %. [9] In line with this, a Swedish study from 2015 on the 
prevalence of AS found a prevalence of 0.24 % in northern Sweden 
compared to 0.16 % in southern Sweden. Total prevalence of AS in Sweden 
was 0.18 %. [10] There are methodological differences that can make 
comparisons between different prevalence studies difficult. Nonetheless, in 
two systematic reviews, the prevalence of AS in Europe was reported to be 
0.23 % and 0.25 % respectively. [11, 12]  
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1.3 CLINICAL PRESENTATION 
The main initial clinical feature of AS is chronic back pain. The definition of 
chronic is duration of more than three months. The pain that often starts at the 
pelvis and the lower back is caused by sacroiliitis. However, inflammation 
can affect all parts of the spine. [2] The pain typical for AS is characterized 
by alternating gluteal pain, insidious onset, improvement with exercise but 
not with rest, pain at night and early mornings, and accompanied by morning 
stiffness. There are several sets of criteria for classification of this 
inflammatory back pain (IBP), partly overlapping (Table 1.). [13-15] The 
sensitivity and specificity for the criteria are around 70-80 %, meaning not all 
patients have this type of back pain, and that other causes of chronic back 
pain can present this way as well. 
Table 1. Inflammatory back pain according to various criteria 
Calin criteria [13] Berlin criteria [14] ASAS criteria [15] 
 To be applied if duration of 
back pain > 3 months and if 
age at onset < 50 years 
To be applied if duration of 
back pain > 3 months 
Age at onset < 40 years  Morning stiffness > 30 
minutes 
Age at onset < 40 years  
Duration of back pain > 3 
months  
Awakening at second half of 
the night because of back 
pain 
Pain at night 
Insidious onset Alternating buttock pain Insidious onset 
Morning stiffness Improvement with exercise 
but not with rest 
No improvement with rest 
Improvement with exercise   Improvement with exercise 
IBP if 4/5 are present IBP if 2/4 are present IBP if 4/5 are present 
IBP; inflammatory back pain, ASAS; Assessment of SpondyloArthritis International Society 
 
In the spine, pathological new bone formation commonly develop in AS, and 
together with inflammation and pain contributes to the limited mobility and 
impaired physical function that often affect these patients. [16-18] In the 
advanced stages of new bone formation, complete ankylosis of the spine can 
develop, often referred to as a “bamboo spine”. [19, 20] 
Non-axial musculoskeletal manifestations of the disease are peripheral 
arthritis, usually an asymmetric oligoarthritis, and enthesitis, both typically 
engaging the lower limbs. [2]. Enthesitis is inflammation at the insertion of 
tendons, ligaments and joint capsules to the skeleton. The heel is the most 
frequently affected entheseal site with inflammation engaging the insertions 
of the Achilles and the plantar fascia. [21] The pooled prevalences of arthritis 
Ankylosing Spondylitis 
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and enthesitis in patients with AS was around 30 % respectively reported in a 
meta-analysis by de Winter. [22] Peripheral enthesitis is usually diagnosed by 
clinical examination assessing tenderness at the entheseal site, a method that 
lacks specificity and objectivity. An imaging tool that can be useful in the 
evaluation of enthesitis is ultrasound (US), which can detect both active 
inflammation and chronic changes at the entheses. [21] Limitations with US 
are discordant data about the ability to differentiate between SpA and other 
conditions and healthy controls, and until recently there was no clear 
agreement on which components to assess and how to define enthesitis. A 
proposed score is under evaluation. [23]  
There are also extra-articular manifestations (EAMs) associated with AS. The 
three most common EAMs are anterior uveitis (AU), IBD defined as Crohn´s 
disease or ulcerative colitis, and psoriasis. AU is inflammation involving the 
iris or ciliary body of the eye. The reported prevalences in AS for AU are 20-
30%, for psoriasis 10-25 % and for IBD 5-10 %. [22, 24-26] More common 
than IBD in patients with AS is the occurrence of microscopic or 
macroscopic subclinical inflammation in the gut, where studies have revealed 
such inflammation in 40-60 % of patients with AS or SpA. [27-29] The heart 
can also be affected in AS. The most common affections are conduction 
disturbances and valvular disease with prevalences ranging from 1-35 % for 
conduction disturbances, 0-34 % for aortic insufficiency (AI) and 5-74 % for 
mitral insufficiency. Higher rates of aortic valve surgery and higher use of 
pacemaker than controls have been reported for AS, whereas the rate of 
mitral valve surgery did not differ. [30] Baseline, cross-sectional reports on 
our cohort showed a prevalence of conduction disturbances between 10-35 % 
depending on if conservative or less conservative criteria were applied, [31] 
and a prevalence of AI of 18 %. [32] Register based studies from our group 
have showed Swedish patients with AS to have an increased risk compared to 
the general population for atrioventricular block II-III, atrial flutter and 
pacemaker implantation, [33] and also an increased risk of acute coronary 
syndrome, stroke and venous thromboembolism. [34] 
1.4 CLASSIFICATION AND DIAGNOSIS 
In clinical studies it is of importance to identify a homogenous, well-defined 
group of patients in order to be able to compare results between studies. The 
classification criteria are traditionally intended to have a high specificity, 
meaning the patients that don´t have the disease will test negative. Diagnostic 
criteria on the other hand are aiming at high sensitivity, meaning to identify 
all individuals with the disease. Diagnostic criteria are generally broader and 
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reflect the different features of the disease and apply to the individual patient, 
whereas classification criteria apply to groups of patients. [35]  
The modified New York criteria were developed for classification and 
diagnosis of AS in 1984. The first criteria for AS were specified at the Rome 
conference in 1963. The criteria were then revised in 1966 to the New York 
criteria and in 1984, the last revision was made and the currently used 
modified New York criteria were defined (Table 2). [36]  
Table 2. The modified New York criteria for ankylosing spondylitis [36] 
Clinical criteria 
-Low back pain and stiffness > 3 months that improves with exercise, but is not relieved by 
rest 
-Limitation of motion of the lumbar spine in the sagittal and frontal planes 
-Limitation of chest expansion relative to normal values correlated for age and sex 
Radiological criterion 
-Sacroiliitis grade ≥ 2 bilaterally or grade 3-4 unilaterally  
 
Definite AS if the radiological criterion is associated with ≥ 1 clinical criterion.  
Probable AS if three clinical criteria are present or if radiological criterion is present without 
signs or symptoms satisfying the clinical criteria.  
 
Table 3. Grading of radiographic sacroiliitis (1966)[37] 
Grade 0: Normal. 
Grade 1: Suspicious changes. 
Grade 2: Minimal abnormality – small localized areas with erosion or sclerosis, without 
alteration in the joint width. 
Grade 3: Unequivocal abnormality – moderate or advanced sacroiliitis with one or more of 
erosions, evidence of sclerosis, widening, narrowing or partial ankylosis. 
Grade 4: Severe abnormality – total ankylosis 
 
The modified New York criteria perform well in patients with established 
disease. However, it takes time to develop radiographic sacroiliitis, so 
patients with early disease cannot be classified or diagnosed with AS. In 
1990 and 1991 two different classification criteria to capture patients with 
undifferentiated SpA were constructed: the Amor criteria and the European 
Spondylarthropathy Study Group (ESSG) criteria (Table 4). [37-39] The 
criteria cover the whole spectrum of the SpA-family and include axial, non-
axial musculoskeletal symptoms and EAMs. These criteria do not distinguish 
between patients with radiographic sacroiliitis or not and the specificity was 
considered too low. [40]  
Ankylosing Spondylitis 
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Table 4. The Amor and the European Spondylarthropathy Study Group 
(ESSG) classification criteria for spondyloarthritis [37-39]  
Amor ESSG 
Criterion (points) Inflammatory spinal pain (IBP according to 
Clinical symptoms or past history:  Calin criteria except age of onset here < 45 
-Lumbar or dorsal pain during the night,  years) 
 or morning stiffness of lumbar or dorsal   
 spine (1) OR 
-Asymmetric oligoarthritis (2)  
-Buttock pain (1) Synovitis (asymmetric or predominantly in 
  if affecting alternatively the right and the   the lower limb) 
  left buttock (2)  
-Sausage-like toe or digit (dactylitis) (2) AND 
-Heel pain or any other well defined enthes-  
  opathy (2) One of the following: 
-Iritis (2) -Family history (first-degree or second-degree 
-Non-gonococcal urethritis or cervicitis  relatives with AS, psoriasis, acute uveitis,  
 accompanying, or within 1 month before,  ReA, IBD 
 the onset of arthritis (1) -Psoriasis, past or present diagnosed by a  
-Acute diarrhea accompanying, or within 1  doctor 
 month before, the onset of arthritis (1) -IBD, past or present, diagnosed by a doctor, 
-Presence of history of psoriasis, balanitis,  confirmed by radiography or endoscopy 
 or IBD (2) -Non-gonococcal urethritis, cervicitis, or  
Radiological finding:  acute diarrhea < 1 month before arthritis 
-Sacroiliitis (grade ≥ 2 if bilateral, grade ≥ 3 -Buttock pain alternating between right and 
 if unilateral) (3)  left gluteal areas 
Genetic background: -Enthesopathy, past or present spontaneous 
-Presence of HLA-B27, or familial history  pain or tenderness at examination site at the 
 of AS, Reiter syndrome, uveitis, psoriasis,   insertion of the Achilles tendon or plantar  
 or IBD (2)  fascia 
Response to treatment: -Sacroiliitis. Bilateral grade 2-4, unilateral  
-Good response to NSAIDs in < 48 h, or   grade 3-4 according to the following  
 relapse of pain in < 48 h if NSAID is   radiographic grading system:  
 discontinued (2)  0 = normal, 1 = possible, 2 = minimal 
Spondyloarthritis if sum score ≥ 6  3 = moderate, 4 = ankylosis 
IBD; inflammatory bowel disease, IBP; inflammatory back pain, NSAID; non-steroidal anti-
inflammatory drug, ReA; reactive arthritis 
 
In 2009, new classification criteria for axial SpA with subdivision in 
radiographic axial SpA and nr-axial SpA were developed: the Assessment of 
SpondyloArthritis international Society (ASAS) criteria. With these criteria, 
patients can be classified either by an imaging arm, which includes magnetic 
resonance imaging (MRI) or an HLA-B27 arm (Table 5). [41] In 2011, 
ASAS presented classification criteria for peripheral SpA (Table 6). [42] 
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Table 5. The Assessment of SpondyloArthritis International Society (ASAS) 
criteria for classification of axial spondyloarthritis [41] 
 To be applied in patients with back pain ≥ 3 months and age at onset < 45 years  
   
 Sacroiliitis on imaging 
plus ≥ 1 SpA feature 
OR HLA-B27 plus ≥ 2 other SpA 
features 
 
     
 SpA features: Sacroiliitis on imaging:  
 -IBP -Crohn´s disease -Active (acute inflammation)  
 -Arthritis -Ulcerative colitis on MRI highly suggestive of  
 -Enthesitis (heel) -Good response to NSAID sacroiliitis associated with   
 -Uveitis -Family history for SpA SpA  
 -Dactylitis -HLA-B27 -Definite radiographic sacro-  
 -Psoriasis -Elevated CRP iliitis according to the 
modified New York criteria 
 
CRP; C-reactive protein, IBP, inflammatory back pain, NSAID; non-steroidal anti-
inflammatory drug 
 
Table 6. The Assessment of SpondyloArthritis International Society (ASAS) 
criteria for classification of peripheral spondyloarthritis [42] 
Arthritis or enthesitis or dactylitis plus 
≥ 1 of OR ≥ 2 of 
-Psoriasis  -Arthritis 
-Inflammatory bowel disease  -Enthesitis 
-Preceding infection  -Dactylitis 
-HLA-B27  -IBP in the past 
-Uveitis  -Positive family history of SpA 
-Sacroiliitis on imaging   
 
1.5 PATHOGENESIS 
Knowledge about the pathogenesis of AS is limited. Genetic factors are 
important and the strong association between HLA-B27 and AS was 
discovered in the early 1970s [43, 44] The majority of genes contributing to 
the risk of developing the disease are still unknown. A recent large genome-
wide association study (GWAS) demonstrated that HLA-B27 and related 
major histocompatibility complex (MHC) variants attributed to 20.4 % of the 
heritability of AS whereas non-MHC variants contributed with 7.4 %. The 
remaining 72.2 % are yet to be identified [45]  
The mechanism of HLA-B27 in the pathogenesis of AS is not established, 
[46] HLA genes encode MHC class I proteins which present peptides to T-
cells. The MHC-I molecules are synthesized, folded and loaded with peptides 
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in the endoplasmic reticulum. The peptides are trimmed to a length preferred 
by MHC-I by the endoplasmic reticulum aminopeptidase (ERAP). [47] The 
first identified non-MHC gene with observed association with AS was 
ERAP1. The association is only found in HLA-B27 positive patients and the 
role of ERAP1 as a trimmer of peptides indicates that HLA-B27 is likely to 
affect AS via a mechanism that involves abnormal presentation of peptides. 
Genetic studies also provide evidence for the involvement of interleukin (IL) 
23 and its downstream pathway with IL-17 and other pro-inflammatory 
cytokines in the pathogenesis of AS. [46]  
Genetics alone cannot explain the onset of the disease. Disturbed barrier 
functions against microbes in the gut and the skin might trigger a pathogenic 
immune response in genetically susceptible individuals. Also, bacteria with 
invasive properties that can penetrate through intact mucosal barriers can 
trigger the immune system in susceptible individuals, as found in ReA. [48] 
The entheses in patients with SpA are prone to inflammation both in the 
spine and the peripheral skeleton and mechanical stress at the enthesis level is 
believed to induce and maybe also maintain inflammation in this patient 
group. [49]  
1.6 MANAGEMENT 
There are international recommendations published for the management of 
SpA from Europe [50] and North America. [51] National Swedish treatment 
guidelines are updated annually (www.svenskreumatologi.se/srfs-riktlinjer). 
The recommendations are similar. General principles for the management of 
AS and nr-axial SpA includes education about the disease, encouragement to 
exercise regularly and to stop smoking. Non-steroidal anti-inflammatory 
drugs (NSAIDs) are the first-line treatment for pain and stiffness. Local 
glucocorticoid injections at the site of inflammation in peripheral joints or 
sacroiliac joints can be used, whereas patients with axial disease should not 
be treated with systemic glucocorticoids. Conventional synthetic disease 
modifying anti-rheumatic drugs (csDMARDs) are not recommended for pure 
axial disease, but sulfasalazine may be considered for treatment of peripheral 
arthritis. When conventional treatment is not sufficient, a biologic DMARD 
(bDMARD) should be considered, and the recommended class of drug is 
tumor necrosis factor inhibitor (TNFi). If TNFi therapy fails, another TNFi or 
switching to an anti-IL-17A therapy should be considered. 
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2 BONE 
2.1 BONE PHYSIOLOGY 
The skeleton has several functions in the body; it gives structural support for 
the rest of the body, serves as attachment sites for muscles and ligaments and 
thereby enables movement and it protects internal organs. The skeleton also 
maintains metabolic homeostasis of minerals such as calcium and phosphate 
and harbors the bone marrow where hematopoiesis takes place. The outer 
shell of the bone is a compact, dens layer called cortical bone. Cortical bone 
surrounds the trabecular bone, which is a rigid network of mineralized bone 
that contains the bone marrow and is more metabolically active than the 
cortical bone. The composition in the skeleton is 80 % cortical bone and 20 
% trabecular bone, with different ratios in different bones. The ratio cortical 
to trabecular bone is 25:75 in the vertebra, 50:50 in the femoral head and 95:5 
in the radial diaphysis. [52] 
Bone strength is determined by several different factors: tissue properties, 
microarchitecture and the whole bone geometry. Tissue properties are 
characteristics such as the degree of mineralization, the degree and type of 
collagen cross-linking and osteocyte density. For the microarchitecture, both 
trabecular and cortical microarchitecture matters. Bone geometry includes 
factors like the bone size, cortical thickness and geometry of the femoral 
neck. [53]  
2.2 BONE CELLS 
There are two categories of bone cells involved in bone formation and 
remodeling, osteoclasts and the osteoblast family. The osteoblast family 
consists of osteoblasts, osteocytes and bone lining cells. The osteoclasts 
resorb bone and are derived from monocyte/macrophage progenitor cells. 
[52, 54] Osteoblasts are bone forming cells originating from the 
mesenchymal cell-line in the bone marrow. Osteoblasts produce osteoid 
composed of bone matrix proteins and mediate calcification of the osteoid. 
They also participate in the regulation of osteoclasts. When the osteoblasts 
have finished the bone formation, some of them are buried in the bone matrix 
and become osteocytes, or they can become lining cells on the bone surface. 
The osteocytes and the lining cells are connected to each other with long 
branches and functions as mechanoreceptors and can regulate osteoblasts and 
osteoclasts [52, 54]  
Bone 
9 
2.3 BONE FORMATION AND REMODELING 
There are two types of physiological bone formation that takes place during 
embryonic development and postnatal growth: endochondral ossification and 
intramembranous ossification. In endochondral ossification, a cartilage 
template is gradually replaced by bone, whereas in intramembranous 
ossification bone is formed directly on a mesenchymal growth plate without 
cartilage intermediate. In both cases, bone matrix is synthesized by 
osteoblasts while osteoclasts degrade the tissue. Most bones are formed by 
endochondral ossification. [55, 56] 
Throughout life, the bones undergo modeling and remodeling. Modeling is 
the process where bones change the overall shape in response to for example 
mechanical forces. Remodeling is more frequent than modeling and is a 
mechanism to preserve the bone strength by replacing older micro-damaged 
bone with new healthier bone, but also to maintain the homeostasis of 
calcium and phosphate. The remodeling cycle begins with recruitment of 
osteoclast precursors that binds to the bone matrix and develops to 
osteoclasts that start the resorption phase. When the resorption phase is 
finished, the osteoclasts undergo apoptosis and osteoblasts start to synthetize 
collagenous matrix which is gradually mineralized to form new bone. [52]  
2.4 REGULATION OF BONE CELLS 
Some of the major mechanisms involved in the regulation of osteoclasts and 
osteoblasts are hereby described (Figure 1). Osteoclast recruitment and 
differentiation are stimulated by macrophage colony-stimulating factor (M-
CSF) and receptor activator NF-κB (RANKL). Osteoclast activation and 
resorption are stimulated by RANKL. Osteoprotegrin (OPG) on the other 
hand inhibits RANKL signaling by acting as a decoy receptor that blocks 
binding of RANKL to its receptor RANK. Factors that can enhance 
osteoclastogenesis driven by RANKL are inflammatory mediators like IL-1, 
tumor necrosis factor α (TNF-α), IL-6 and prostaglandin E2 (PGE2). [57] 
Osteoblast precursors are recruited by growth factors like insulin-like growth 
factor 1 (IGF-1) and transforming growth factor-β (TGF-β). Osteoblast 
differentiation and survival is stimulated by bone morphogenetic proteins 
(BMPs) and WNTs. WNTs are inhibited by sclerostin and dickkopf1 (DKK1) 
and BMPs are inhibited by noggin. Osteoblasts participate in the regulation 
of osteoclasts by expressing RANKL, M-CSF and OPG [58-60] 
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The mechanism how osteocytes control and regulates osteoblasts and 
osteoclasts is not fully elucidated but two important factors are RANKL and 
sclerostin. [58]  
In the initiation of endochondral ossification, chondrocyte proliferation and 
hypertrophy is stimulated by proteins as Hedgehog, WNTs and BMPs. When 
the chondrocytes die, blood vessels invade the tissue together with 
osteoblasts and osteoclasts. Important stimulatory factor for the angiogenesis 
is vascular endothelial growth factor (VEGF) whereas RANKL promotes 
invasion of osteoclasts. WNTs and BMPs are stimulating the osteoblasts. [61] 
 
Figure 1. Some of the major mechanisms involved in the regulation of osteoclasts 
and osteoblasts 
Bone 
11 
2.5 NEW BONE FORMATION IN ANKYLOSING 
SPONDYLITIS 
AS is characterized by pathological spinal new bone formation with 
development of syndesmophytes and a risk of developing total ankylosis. The 
AS related spinal alterations can be visualized on plain radiographs and the 
preferred method to grade these changes in clinical studies is by the modified 
Stoke Ankylosing Spondylitis Spine Score (mSASSS). [62-64] The score 
ranges from 0 to 72. [65] Not all patients with AS develop AS related spinal 
alterations and the progression rate over time is highly variable between 
patients [66] but also in the same patient over time. [67] Commonly reported 
progression rates in different cohorts of patients with AS are progression of 
mean 1 mSASSS/year [66, 67] or between mean 0.8-1.5 mSASSS/2 years. 
[68-71] More AS related spinal alterations are found in men compared to 
women. [72-74] 
The knowledge of the mechanisms of the pathological new bone formation in 
AS is limited and research in this area is hampered by the difficulties in 
obtaining biopsies from the affected tissues, the slow process of new bone 
formation and the restricted sensitivity to change for mSASSS. [75] 
There are different theories about the relation between inflammation and 
spinal new bone formation. Some researchers have proposed that the process 
is always initiated with inflammation at the spine, osteitis, and is then 
followed by a repair mechanism that replaces the subchondral bone marrow 
with granulation tissue from which stimuli for new bone formation is 
released. [75] Other researchers have proposed the new bone formation to be 
at least partly uncoupled from inflammation. One such theory is that 
inflammation at the spine causes loss of trabecular bone which affects the 
microarchitecture and stability of the vertebra. As a consequence in an 
attempt to stabilize the spine, new bone formation is hypothesized to occur. 
In this theory, inflammation is thought to start with mechanical stress causing 
micro damage at the enthesis level. [76, 77] Both research theories consider 
BNPs, WNTs and Hedgehog proteins to be of importance on the molecular 
level in the stimulation of new bone formation and that dysregulation of 
inhibitors of bone formation such as sclerostin, DKK1 and noggin also can be 
involved. [2, 78] 
New bone formation in AS takes place in connection with existing bone but 
extends outside the normal shape and is a complex remodeling process. Both 
endochondral and intramembranous bone formation seem to contribute. [79]  
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2.5.1 HISTOPATHOLOGIC STUDIES 
Histopathologic material from the axial skeleton has mainly been obtained 
from facet joints from AS patients with total ankylosis undergoing surgery 
due to hyperkyphosis and from biopsies from SI-joints. A process found in 
the facet joints, was growth of fibrous granulation tissue from the bone 
marrow. The fibrous granulation tissue invaded the subchondral bone plate 
and reached the cartilage where spots of new bone were formed. The invasion 
seemed to be facilitated by osteoclasts and the granulation tissue carried 
osteoblasts with bone forming capacities. They also found replacement of the 
subchondral bone marrow by fat tissue. However, fat tissue without 
granulation tissue was not associated with new bone formation. [80-82] A 
recent study aimed at specifically analyze the fatty lesions seen on MRI by 
immunohistological analyses of anterior vertebral edges. Fatty lesions were 
found to correspond to the presence of adipocytes and to have a high number 
of osteoblasts, whereas dominance of osteoclasts was found in the MRI 
inflammatory lesions. [83] Another research-group found signs of persistent 
inflammation with aggregates of both T-cells and B-cell and signs of 
neoangiongenesis in the bone marrow of facet joints despite patients having 
complete ankylosis. [84] 
A large biopsy study on SI-joints in early axial SpA found the most common 
feature to be pannus formation of highly vascular granulation tissue from the 
synovium or bone marrow with invasion of the subchondral bone plate. They 
also found some signs of endochondral ossification with new bone formation 
at the bone-cartilage interface and some signs of enthesitis. [85] Francois et 
al. analyzed different stages of sacroiliitis, and summarized that synovitis and 
subchondral granulation tissue from the bone marrow gradually destroys and 
replaces the articular cartilage and subchondral bone. Some signs of 
enthesitis were found but were not considered important in the process. They 
found evidence of both endochondral and intramembranous bone formation 
but also an unusual form of chondroid metaplasia. [86] 
2.5.2 BIOMECHANICAL FACTORS 
Enthesitis has been proposed to be the primary disease location in the 
different SpA subtypes. [87] The entheses, especially at the spine and the 
lower limbs are exposed to mechanical loading and subjected to micro 
damage. It has been hypothesized that mechanical stress is an initial trigger 
for inflammation through micro damage at the enthesis. [78] In a mouse 
model of SpA, inflammation started at the entheses and then spread to the 
synovium, finally involving the whole joint. When mice were tail-suspended 
with hind limbs unloaded, no inflammation developed. In a second mouse 
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model, new bone formation developed mainly at the entheseal sites and tail 
suspension led to less new bone formation. [88] Recently, Cambré et al. 
showed in other mice models that unloaded limbs did not develop arthritis, 
that higher grade of loading by voluntary running led to enhanced 
inflammation and that inflammation developed especially at sites with high 
mobility and rich in attachment sites for tendons. [89] Another important 
mouse study by Sherlock et al. found evidence that IL-23 over-expression 
induced enthesitis by acting on a specific entheseal resident T-cell, identified 
at the entheses and the aortic root. [90] These T-cells responded to systemic 
expression of IL-23 and severe entheseal inflammation and entheseal new 
bone formation developed both at the paws and at the attachment of the 
spinal ligaments. Also, inflammation at the aortic root and valve developed. 
The resident T-cells were also shown to produce IL-17 and IL-22 after 
stimulation with IL-23. How these results can be applied in human disease 
needs further research. 
There are two clinical studies on patients with AS which indicate that 
mechanical stress might be involved in the pathogenesis of spinal new bone 
formation. One cross-sectional study on patients with disease duration ≥ 20 
years showed that patients whose previous occupations had required dynamic 
flexibility or exposure to whole body vibration had significantly more AS 
related alterations in the spine. [91] A longitudinal study by Ramiro et al. 
investigated the effect of mechanical stress on spinal radiographic 
progression by using type of occupation divided into blue collar (physically 
demanding) and white collar (sedentary) labor. The direct effect of the type 
of occupation on radiographic progression was weak. In an indirect analysis 
they showed that blue collar work amplified the effect of inflammation on 
new bone formation. [92] 
2.5.3 MAGNETIC RESONANCE IMAGING 
Researchers have used MRI to explore the relation between inflammatory 
lesions in the vertebrae and the association with development of new bone 
formation in the spine. MRI studies have shown that inflammatory lesions 
with bone marrow edema in the vertebral corners can predict the 
development of new syndesmophytes. [93, 94] Syndesmophytes also develop 
in vertebral corners with fatty degeneration, generally believed to represent 
some kind of repair tissue. [95] In patients treated with TNFi, acute 
inflammatory lesions resolved without sequelae while more advanced 
vertebral inflammatory lesions that had started to show signs of reparative 
changes (fatty lesions) progressed to new bone formation. [96] Baraliakos et 
al. found that inflammation and fatty lesions in combination had the highest 
risk for new syndesmophytes. However, most of the new syndesmophytes 
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developed without signs of pathological MRI-findings at baseline. [97] It is 
difficult to draw definitive conclusions from MRI studies since lesions can 
occur and disappear between examinations and a histopathologic study 
revealed that a substantial degree of bone marrow inflammation is necessary 
for detection on MRI. [98] 
2.5.4 BIOMARKERS AND RADIOGRAPHIC PROGRESSION 
One indication that inflammation is involved in the process of spinal new 
bone formation is studies of C-reactive protein (CRP) as a predictor of 
radiographic progression. There are several studies showing inflammation 
measured by CRP to predict spinal new bone formation in patients with AS 
and nr-axial SpA, both elevated baseline CRP and elevated time-averaged 
CRP. The association of elevated CRP and new bone formation was found 
despite differences in use of TNFi and disease duration in the cohorts. [68, 
99-102] Other serum biomarkers of inflammation that have been shown to 
predict spinal radiographic progression are IL-6 and serum calprotectin. [103, 
104]  
Macrophage migration inhibitory factor (MIF) was found to predict spinal 
radiographic progression and additional experiments suggested that MIF has 
a direct role in enhancing mineralization by osteoblasts. [105] MIF has been 
studied in one cohort of patients. A not so uncommon feature of biomarker 
studies is the inability to reproduce the results in other cohorts. Elevated 
matrix metalloproteinase 3 (MMP3) and VEGF were found to predict spinal 
radiographic progression over 2 years, especially in patients with presence of 
AS related spinal alterations at baseline. [106, 107] However, VEGF lacked 
predictive value in patients treated with TNFi and results were not confirmed 
for MMP3 in another cohort. [108, 109] In two relatively small studies, low 
serum levels of functional DKK1 [110] and low levels of sclerostin predicted 
spinal radiographic progression. [111] Result for sclerostin was not 
reproduced. [109] Elevated levels of the adipokine visfatin as a predictor of 
spinal radiographic progression could not be repeated either. [112, 113] An 
inverse relationship between the adipokines leptin and high molecular weight 
adiponectin (HMW-APN) and spinal radiographic progression has been 
found [113] and a recent publication confirmed this relationship and also 
found higher levels of VEGF in patients with radiographic progression. The 
combination of VEGF, leptin and HMW-APN had the best predictive ability 
of spinal radiographic progression. However, the added value to clinical 
parameters was rather small. [109]. So far, no biomarker except CRP is used 
in clinical practice.  
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2.5.5 HEPATOCYTE GROWTH FACTOR 
There are two studies on hepatocyte growth factor (HGF) in AS. An 
association was found for high levels of HGF and increased disease activity. 
[114] In our cohort, patients with AS had higher levels of serum HGF (s-
HGF) than healthy controls, and higher s-HGF was associated with higher 
mSASSS in the baseline cross-sectional analysis.[115] Higher levels of s-
HGF compared to controls have also been found in patients with rheumatoid 
arthritis (RA), IBD and systemic lupus erythematosus (SLE). [116-119] 
Patients with RA had higher level of HGF in synovial fluid compared to 
peripheral blood, [120, 121] and high plasma HGF predicted progression of 
erosion and joint space narrowing in the finger joints in patients with RA. 
[122] Whether HGF has a mechanistic role in rheumatic diseases, or if HGF 
is upregulated in response to pro-inflammatory cytokines is not clear. Studies 
have shown HGF to affect immune cells, and in different animal models 
HGF prevents and attenuates inflammatory diseases, [123] for example 
collagen induced arthritis and experimental colitis. [124, 125]  
HGF can affect a variety of cells in many different organs, and can stimulate 
cell proliferation, survival, motility and promotes angiogenesis. [126] HGF is 
required for self-repair after injuries of skin, muscle and cartilage. [127] 
Therapeutic effects of recombinant HGF has been shown in many different 
animal models for diseases in organs like the liver, the kidneys, the lungs, the 
skin and the cardiovascular system. [128] During tissue repair, several 
cytokines like IL-1, IL-6 and TNF-α induce transcription of HGF and its 
receptor cellular MET (cMET). [129] Knowledge about the role of HGF in 
regulation of bone cells is limited. Both osteoclasts and osteoblasts express 
HGF and cMET [130-132] and HGF stimulates migration of osteoclasts. 
[131] There are studies indicating an osteogenic effect of HGF; HGF in 
combination with vitamin D or alone was shown to promote differentiation of 
osteoblasts and to be important for mineralization. [133, 134] In animal 
models, HGF improved fracture healing. [135, 136] However, there are also 
studies reporting that HGF inhibits osteogenic differentiation. [137]  
2.5.6 FACTORS ASSOCIATED WITH SPINAL 
RADIOGRAPHIC PROGRESSION 
Several longitudinal, observational cohort studies on patients with AS or nr-
axial SpA have assessed predictors for spinal radiographic progression. The 
follow-up time and intervals for radiographs differ, but an interval of at least 
2 years between radiographs is needed to detect changes in mSASSS. [138] 
The strongest and the most commonly detected predictor is presence of AS 
related spinal alterations at baseline, most commonly ≥ 1 syndesmophyte. 
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[66, 68, 74, 100, 139-141] Other reported independent predictors for spinal 
radiographic progression are smoking, [99, 140, 142] male sex, [67, 69, 143], 
history of uveitis, [143] drinking alcohol (vs not drinking), [143] and low 
bone mineral density (BMD). [140] Increased disease activity, especially 
measured by Ankylosing Spondylitis Disease Activity Score based on CRP 
(ASDAS_CRP) at baseline and over time has also been shown to be 
associated with radiographic progression. [102, 144] The effect of 
ASDAS_CRP on progression was higher in men than women, [102] in 
smokers versus non-smokers and in blue collar workers vs white collar 
workers. [92]  
2.5.7 TREATMENTS AND SPINAL RADIOGRAPHIC 
PROGRESSION 
There is yet no treatment proven to be very effective in haltering 
development of AS related spinal alterations. One randomized controlled trial 
(RCT) comparing the effect of continuous vs on-demand treatment with 
NSAID found continuous use of NSAIDs to reduce the spinal radiographic 
progression over two years. [145] However, another RCT with the same 
design but with diclofenac instead of celecoxib found no such effect. [71] 
Whether different effect on radiographic progression is related to different 
cyclooxygenase (COX)-selectivity is not elucidated.  
The question if TNFi have effect on spinal radiographic progression is 
difficult to answer since radiographic progression is slow and long term 
RCTs comparing treatment with TNFi versus no treatment in patients in need 
of such treatment would be unethical. [146] Initial studies on use of TNFi 
versus another historical TNFi-naïve cohort failed to prove an effect on spinal 
radiographic progression. [147-149] There are now some reports from 
observational studies that show treatment with TNFi to retard radiographic 
progression, especially when TNFi is used for a longer time period [69, 99, 
150] and initiated early in the disease course. [99] 
Quite recently, the IL-17A inhibitor secukinumab was introduced as a 
treatment option for AS. Data about the effect on spinal radiographic 
progression are limited. There is one study that compared radiographic 
progression in patients treated with secukinumab for two years with TNFi-
naïve patients from a historic cohort treated with NSAIDs. No significant 
differences in progression between groups were found. [151] 
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2.6 OSTEOPOROSIS 
Osteoporosis is defined as a systemic skeletal disease characterized by low 
bone mass and deterioration of the microarchitecture with a consequent 
increase in bone fragility and susceptibility to fractures. [152] A persons bone 
mass later in life is determined by the peak bone mass accumulated up to 
puberty and the subsequent rate of bone loss. Bone loss occurs because of an 
imbalance between the activity of osteoclasts and osteoblasts. Estrogen is 
important in normal bone remodeling. During menopause when estrogen 
levels decrease, bone loss occurs at a higher rate. [153] Declining levels of 
bioavailable levels of estrogen may also be an important factor in age-related 
bone loss in men and declining levels of testosterone might also contribute. 
[154] Other age-related mechanisms of bone loss are secondary 
hyperparathyroidism, declining muscle mass and reduced mechanical 
loading. [153]  
Diagnosis of osteoporosis is made based on measurement of BMD. BMD in 
an individual can be expressed in relation to the mean of a reference 
population in standard deviations (SD). The T-score is the SD expressed in 
relation to a young, healthy population. The Z-score is the comparison with 
the same age and sex group. A definition of osteoporosis was developed by 
the World Health Organization (WHO) in 1994 for post-menopausal women 
based on T-score in comparison to young women. They established the 
following four categories for assessments done using dual-energy x-ray 
absorptiometry (DXA); normal: T-score > -1 SD, low bone mass or 
osteopenia: T-score < -1 SD to > -2.5 SD, osteoporosis: T-score ≤ -2.5 SD, 
and severe osteoporosis: T-score < -2.5 SD and ≥ 1 fragility fracture. [155] 
The definition is now applied also on men ≥ 50 years old and women in 
menopausal transition. Measurements at the total hip, femoral neck and 
lumbar spine are primarily used, but measurements at radius can be used for 
diagnosis if the other sites are not assessable 
(www.iscd.org/officialpositions). For premenopausal women and men < 50 
years a Z-score ≤ -2 SD is defined to be below expected range for age. [156] 
The prevalence of osteoporosis in Sweden in the age group 50-80 years based 
on BMD-measurements at the femoral neck has been reported to be 6.3 % for 
men and 21.2 % for women. [157] 
2.7 FRACTURES 
Osteoporosis is a silent disease until complicated by fractures preceded by 
little or no trauma. The most common fractures associated with osteoporosis 
are the so called major osteoporotic fractures at the hip, spine (clinical), 
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forearm and proximal humerus, [158] but almost all types of fractures are 
increased. Especially hip fractures but also vertebral fractures (VFs) are 
associated with increased mortality, morbidity and loss of function. Both hip 
fractures and VFs increase the risk of subsequent fractures. [159, 160] Many 
VFs occur un-diagnosed and there are two types of definitions: clinical 
fractures and cases where radiographs show vertebral deformities. [161] 
Incidence of fractures varies between populations worldwide with the highest 
risk of hip fractures in the Nordic countries. [162] The highest incidence of 
morphometric VFs (based on measurements of vertebral heights using 
imaging) among European countries was found in Sweden. [163] The 
majority of osteoporotic fractures occur in elderly women. [164] 
There are many conditions, diseases and medications that contribute to 
osteoporosis and fractures, some of them are listed in Table 7. [160, 165]  
Table 7. Some lifestyle factors, diseases and medications that contribute to 
osteoporosis and fractures  
Lifestyle factors:    
Alcohol abuse Smoking Low physical activity 
Low calcium intake Vitamin D insufficiency  
Genetic diseases:   
Cystic fibrosis Ehler-Danlos Marfan syndrome 
Hypogonadal states   
Anorexia nervosa Menopause < 40 years old Athletic amenorrhea 
Hypogonadism   
Endocrine disorders:   
Hyperparathyroidism Cushing´s syndrome Acromegaly 
Diabetes mellitus Thyrotoxicosis  
Gastrointestinal diseases:   
Celiac disease IBD Gastric bypass surgery 
Primary biliary cirrhosis End stage liver disease  
Neurological diseases   
Multiple sclerosis Epilepsy Parkinson´s disease 
Rheumatic diseases:   
Rheumatoid arthritis SLE  
Other diseases   
End-stage renal disease Chronic obstructive lung disease 
Medications:    
Glucocorticoids Proton pump inhibitors SSRI 
Anticoagulants (heparin) Anticonvulsants Loop diuretics 
SSRI; selective serotonin reuptake inhibitor 
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2.8 MEASUREMENT OF BONE MINERAL 
DENSITY 
Bone consists of mineral, mainly calcium hydroxyapatite, embedded in the 
matrix. The matrix consists of collagen type I and different proteins. Calcium 
absorbs much more radiation than the matrix, and the amount of x-ray energy 
that is absorbed by calcium reflects the bone mineral content (BMC). BMD is 
estimated by BMC divided by the area or volume of the bone. Areal BMD 
(aBMD) is the average of mineral per unit area (g/cm2) and volumetric BMD 
(vBMD) is the average of mineral per defined volume of bone (g/cm3). [166] 
2.8.1 DUAL-ENERGY X-RAY ABSORPTIOMETRY 
DXA is the most commonly used technique to assess BMD and is used in 
clinical practice for diagnosis of osteoporosis according to WHO. The hip, 
lumbar spine, forearm and whole body can be measured. DXA typically 
assesses aBMD, a measurement dependent of the size of the bone; a larger 
bone with the same mineral density as a smaller bone will have higher 
aBMD. The projection normally used for the spine is the anteroposterior (AP) 
projection which includes the posterior elements of the spine, the facet joints 
and also the abdominal aorta. Aortic calcifications and osteoarthritis in the 
spine can result in a false high BMD of the spine. [166] One way to 
overcome this is to measure BMD in the spine by the lateral projection which 
excludes the posterior elements and the abdominal aorta and primarily 
assesses the trabecular bone. [167] Studies have shown BMD by lateral DXA 
to be less affected by degenerative joint disease than AP DXA. [168, 169] 
There is no reference material with T-scores and Z-scores for the lateral 
projection for men. If lateral and AP projections are combined, an estimation 
of vBMD can be obtained. [170] 
2.8.2 HIGH-RESOLUTION PERIPHERAL QUANTITATIVE 
COMPUTED TOMOGRAPHY 
High-resolution peripheral quantitative computed tomography (HRpQCT) is 
mainly used for research purposes and is not used in clinical practice. With 
HRpQCT, vBMD at the distal tibia and radius can be obtained for the whole 
bone and separately for cortical and trabecular bone. In addition, the 
microarchitecture of the cortical and trabecular bone and bone geometry can 
be assessed. Based on HRpQCT images, bone strength can be estimated 
using finite element analysis. There are no reference values such as T-scores 
or Z-scores for HRpQCT measurements. [171] 
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2.8.3 OTHER METHODS OF ASSESSMENT  
There are other methods of assessment of bone density that are not used in 
routine clinical practice in the diagnosis of osteoporosis. Quantitative 
computed tomography (QCT) also assesses vBMD and can separate 
trabecular bone from cortical bone. [172] QCT can be used for measurements 
both at the appendicular skeleton and the spine. The method is more useful 
for spinal measurements since the false increase in BMD by for example 
degenerative disease can be avoided. However, disadvantages compared to 
DXA are higher cost and higher exposure to radiation. [173] The Trabecular 
bone score (TBS) can be computed using the DXA image of the AP spine. It 
is an evaluation of grey-level texture variations in the image and gives an 
indirect index of the microarchitecture and an overall score is computed. TBS 
can be used for fracture prediction in association with the Fracture Risk 
Assessment Tool (FRAX®) and aBMD in postmenopausal women and men > 
50 years. Limitations are the lack of a well-established cut-off value for 
defining normal values and TBS is influenced by body mass index (BMI) and 
body composition and can only be assessed in patients with BMI in the range 
of 15-37 kg/m2. [174, 175] Quantitative ultrasound (QUS) does not involve 
any radiation but measures attenuation of ultrasound and speed of sound and 
gives a reflection of the bone density and structure. The method is mostly 
applied at the calcaneus. [176] Measurements from different scanners are not 
comparable to each other and there is no international consensus on how to 
define osteoporosis with QUS. [177] 
2.9 OSTEOPOROSIS AND ANKYLOSING 
SPONDYLITIS 
There are many cross-sectional studies on the prevalence of osteoporosis or 
low BMD in patients with AS or SpA and many studies show lower BMD in 
patients compared to age- and sex-matched reference values or controls, 
which could seem paradoxical considering that spinal new bone formation 
and ankylosis is a hallmark of the disease. The reported prevalences of low 
BMD differs between cohorts and ranges from 4 % to 58 %. [178] Reasons 
for differences in prevalences can be differences in the severity of the 
disease, the age and disease duration of the studied patients, the underlying 
diagnosis and the technique used to evaluate BMD. However, low BMD and 
osteoporosis is found also in patients with early disease, with ranges of 
prevalences of osteoporosis in 3 - 29 % and of osteopenia in 14-56 % of the 
patients with disease duration < 10 years. [179] The cross-sectional baseline 
report from our cohort showed a prevalence of osteoporosis of 21 % and 
osteopenia of 44 % in the patients > 50 years old, whereas a BMD below 
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expected range for age was found in 5 % of the patients < 50 years old. 
Osteoporosis was more prevalent in women (30 %) than men (14 %) whereas 
BMD below expected range for age was equally prevalent in women and men 
in patients < 50 years old. [180] 
2.10 MEASUREMENT OF BONE MINERAL 
DENSITY IN PATIENTS WITH ANKYLOSING 
SPONDYLITIS 
In patients with radiographic AS related spinal alterations, BMD can be 
falsely high when measured at the lumbar spine AP projection. Patients with 
AS related spinal alterations have been shown to have higher aBMD when 
measured with the AP projection compared to patients without such 
alterations. [20, 181, 182] Patients without AS related spinal alterations were 
shown to have lower aBMD at the AP spine compared to healthy controls 
whereas aBMD for patients with radiographic changes did not differ 
compared to controls, [183] and spinal radiographic alterations have been 
shown to be positively correlated to aBMD at the spine. [184, 185] European 
League Against Rheumatism (EULAR) management guidelines for use of 
imaging in SpA have recommended that osteoporosis should be assessed by 
hip DXA in patients with syndesmophytes in the lumbar spine and 
supplemented by either spine DXA in lateral projection or by QCT of the 
spine. [186] The few cross-sectional studies on lateral DXA of the spine in 
AS have shown that lateral BMD was lower in AS patients in comparison 
with controls, whereas AP BMD did not differ. [185, 187, 188] One of the 
studies also grouped the patients in late and early disease and found in 
comparison with controls, lower lateral BMD in both groups whereas only 
the group with early disease had lower AP BMD. The only measuring site 
that differed between patients with and without syndesmophytes was the 
lateral spine. [188] In this current cohort, baseline analyses showed more 
women to be diagnosed with osteoporosis with lateral BMD than AP BMD. 
Reference values for men were lacking. [180] Studies on QCT in AS patients 
are also limited and three studies included ≤ 15 patients. [183, 189, 190] 
Studies have shown trabecular vBMD measured by QCT to be less affected 
by new bone formation than aBMD by AP DXA [182, 190] and higher 
frequency of osteoporosis/osteopenia or lower Z-score was detected by QCT 
in patients with syndesmophytes vs patients without syndesmophytes. [191, 
192] Over 10 years, trabecular vBMD by QCT had decreased but aBMD by 
AP DXA increased in 15 patients with AS. In the group with more advanced 
radiographic spinal alterations, trabecular vBMD was lower compared to 
patients without AS related spinal alterations. However, in multivariate 
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analyses, radiographic alterations were not associated with bone loss by 
QCT. [189] 
2.11 FACTORS ASSOCIATED WITH CHANGES 
IN BONE MINERAL DENSITY IN PATIENTS 
WITH ANKYLOSING SPONDYLITIS 
Longitudinal cohort studies on changes in BMD (∆-BMD) using DXA in 
patients with AS differ in follow-up time, age of the patients, duration and 
severity of the disease, presence of AS related spinal alterations and 
treatments, among other factors. There are some studies of patients without 
treatment with TNFi that show an association between inflammation and 
bone loss. Two studies had similar patient groups in age and disease duration, 
they also excluded patients with vertebral ankylosis and stratified patients in 
persistent active or inactive disease based on CRP/erythrocyte sedimentation 
rate (ESR). One of the studies found that patients with persistent active 
disease decreased in AP lumbar spine and femoral neck BMD whereas BMD 
in patients with inactive disease did not change over time. Elevated CRP was 
found to be independently associated with bone loss at the lumbar spine. 
[193] The other study found decreases in femoral neck BMD, with greater 
reduction in the active group vs the inactive group. AP spine BMD did not 
change in either group. [194] In patients with very early IBP without 
radiographic sacroiliitis, there were no changes in BMD at total hip, femoral 
neck, lumbar spine AP or the hand in the total group, however, in the group 
with persistent high CRP, femoral neck and total hip BMD decreased with 
significant difference from the group with normal CRP. [195]  
Other studies on patients without TNFi have included patients no matter the 
severity of AS related spinal alterations. One such study found BMD at the 
AP spine, femur (probably total hip) and forearm to increase significantly 
over time. Elevated ESR during follow-up and hip involvement were reported 
to be associated with decreases in spinal and femoral neck BMD. The 
association between AS related spinal alterations and ∆-BMD was not 
investigated. [196] Another study stratified AS patients in active and inactive 
disease based on Bath AS Disease Activity Index (BASDAI). No differences 
in ∆-BMD between groups were observed in AP spine, femoral neck or total 
hip BMD. Overall, AP spine BMD increased, as did SASSS (Stoke AS Spine 
Score, which assesses only the lumbar spine) but the authors reported no 
significant relationship between ∆-SASSS and ∆-BMD. [197] Several studies 
on patients treated with TNFi, did not find a relationship between AS related 
spinal alterations and ∆-BMD either. [198-200] Only one longitudinal study 
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found such a relationship; increases in SASSS was associated with increases 
in AP spine BMD. Additionally, patients with combination of TNFi and 
bisphosphonates increased more in SASSS compared to patients treated with 
TNFi alone, whereas no difference in ∆-SASSS was found when comparing 
use of bisphosphonates or not in patients without TNFi. [201] 
Most studies on changes in BMD aim at exploring the role of TNFi on BMD. 
One meta-analysis on the effect of TNFi on changes in spine and hip BMD in 
patients with AS, reported that AP lumbar spine BMD and total hip BMD 
had increased after 1 year of treatment and further increased the second year. 
Femoral neck BMD remained stable after 1 year; there were not sufficient 
data for analyses of 2 year changes. [202] Studies published after that meta-
analysis also show increases in AP spine BMD [199, 203-205], total hip 
BMD [199, 205] as well as femoral neck BMD for patients treated with 
TNFi. [204] One study showed use of NSAID to have a protective effect on 
bone loss at total hip in patients with early inflammatory back pain 
suggestive of SpA, both in patients with and without TNFi. Additionally, in 
patients without TNFi, a 2 year increase in BMI was protective for bone loss. 
[206]  
Studies on the effect of bisphosphonates on changes in BMD in AS patients 
are scarce. Studies vary in length from 6 months to 2 years and included 
between 12 to 34 patients with bisphosphonate treatment. Results are 
conflicting. In a 6 month study on disease activity in AS, patients were 
randomized to the TNFi infliximab or intravenous bisphosphonate 
neridronate. Patients treated with neridronate increased in AP lumbar spine 
BMD whereas no change was observed in patients treated with infliximab. 
No significant changes in femoral neck BMD or total hip BMD were 
observed. [207] One observational cohort study found indications of a 
synergistic effect of oral bisphosphonates and TNFi on increases in BMD, 
but only at the greater trochanter. [208] Two studies could not find an effect 
on BMD by bisphosphonate treatment. [201, 209] The IL-17A inhibitor has 
not been studied in regards of changes in BMD.  
2.12 FRACTURES IN PATIENTS WITH 
ANKYLOSING SPONDYLITIS 
2.12.1 VERTEBRAL FRACTURES 
There are many studies on VFs in patients with AS and the prevalence in 
different studies varies from 0.9 % to 39 %. [210] The prevalence of VFs 
found on radiographs in this current cohort at baseline was 12 %. [192] 
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Patients with AS have been shown to have an increased risk of VFs 
compared to controls, both regarding morphometric fractures [211, 212] and 
clinical fractures. [213] Patients with AS are used to spinal pain, and spinal 
fractures can be overlooked by the patient and the doctor. Patients with a 
fused or partly fused spine due to AS related spinal alterations are susceptible 
to severe spinal fractures even after low energy trauma, mainly in the cervical 
spine. Due to ossification of supportive soft tissues, the fractures have the 
risk of being unstable and may dislocate and cause neurological deficit. [214] 
Plain radiographs in these patients may also fail to detect the fracture due to 
the ossifications. [215]  
A recent meta-analysis to examine the risk of VF and non-vertebral fractures 
found that patients with AS had almost double the risk of VFs when 
compared to non-AS subjects. The risk remained the same when analyses 
were stratified in morphometric and clinical fractures. [210] In the meta-
analysis they found prevalent VFs to be associated with lower BMD at the 
femoral neck and total hip, but not at the lumbar spine. BMD at the forearm 
was also lower in patients with VFs, however, only two studies with 
relatively small number of fractures assessed this measuring site and further 
studies are needed. Also, older age, male sex, longer disease duration, more 
AS related spinal alterations and IBD were risk factors for prevalent VFs. 
[210] Data regarding the association between NSAID-use and VFs are 
conflicting. [70, 213, 216-218] 
There are some longitudinal studies assessing the effect of TNFi on 
development of new VFs, however, number of patients who develop new 
VFs are relatively small. Despite improvement in BMD and decreases in 
disease activity with TNFi, VFs continued to develop with up to 20 % of 
patients developing new VFs with up to 4 years of treatment. [199, 203, 205] 
Two studies found no significant difference in frequency of new VFs 
between patients with and without TNFi. [216, 219] Variables reported to be 
independently associated with development of new VFs over 4 years were 
baseline VFs and increases in CRP at the 2-year control. [216] Two studies 
did not conduct multivariate analyses; in univariate analyses, both studies 
found new or progressive VFs to be associated with older age and lower AP 
spine BMD. Additionally, new VFs over 2 years were associated with lower 
total hip BMD and less use of NSAIDs at baseline [219], whereas new VFs 
over 4 years were associated with longer duration of smoking, higher Bath 
AS Functional Index (BASFI), presence of VFs and use of anti-osteoporotic 
treatment at baseline. [203] One longitudinal study found no variables 
associated with incident VFs. [199] 
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2.12.2 NON-VERTEBRAL FRACTURES 
Non-vertebral fractures in patients with AS are less studied than VFs. The 
aforementioned meta-analysis on fracture risk in patients with AS found the 
risk of non-vertebral fractures to be 10 % higher in AS patients compared to 
controls. The result was based on 3 studies. Two studies compared the 
frequency of hip fractures between AS and controls, and the meta-analysis 
showed no significant difference between AS and controls. No analyses 
regarding factors associated with non-vertebral fractures could be done. [210] 
One study has reported risks of fractures at radius/ulna for AS patients, and 
did not find the risk to be significantly higher in AS patients compared to 
controls. [213] 
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3 AIMS 
The general aims of this thesis were to study the development of bone loss 
and new bone formation over 5 years in a cohort of patients with AS, as well 
as to assess factors associated with the changes.  
The specific aims of the papers included in the thesis were: 
I. To evaluate changes in aBMD measured by DXA at the 
lumbar spine, both the AP and lateral projections, the total 
hip, femoral neck and total radius and to assess disease-
related variables and medications associated with the 
changes in BMD.  
II. To evaluate the progression of AS related spinal alterations 
and to assess predictors for the progression overall and by 
sex. 
III. To evaluate changes in trabecular and cortical vBMD, 
cortical area and microarchitecture at tibia and radius 
measured by HRpQCT in men with AS and to assess factors 
associated with changes in vBMD and cortical area.  
IV. To study associations of baseline s-HGF and the average s-
HGF with progression of AS related spinal alterations 
overall and by sex and to assess factors correlated with 
changes in s-HGF.  
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4 PATIENTS AND METHODS 
This thesis is based on a longitudinal, prospective study on a cohort of 
patients with AS.  
4.1 PATIENTS 
All papers in this thesis are based on a cohort of patients recruited at baseline 
from the rheumatology clinics at Sahlgrenska University Hospital in 
Gothenburg and the hospitals at Borås and Alingsås in Sweden. The 
recruitment procedure has been described in detail in a previous report. [180] 
Medical records of all patients with AS registered in the hospitals’ databases 
were assessed for eligibility of the study. Inclusion criterion was AS 
according to the modified New York criteria. [36] Exclusion criteria were 
psoriasis, IBD, dementia, difficulties in understanding the Swedish language 
and ongoing pregnancy. In total, 204 patients completed DXA, X-rays of the 
spine, blood samples, medical examination and questionnaires at baseline and 
were invited to the 5-year follow-up. Results from the follow-up are reported 
in paper I, II and IV. The flow chart of participation is shown in Figure 2.  
Figure 2. Flow chart of participation from baseline to the 5-year follow-up for 
assessment with DXA, radiography and serum HGF  
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Paper III. Of the 204 patients, 69 men were also randomized in an age-
adjusted algorithm to undergo HRpQCT at baseline. Of these 69 men, 2 were 
deceased and 10 declined participation, did not respond to invitation or did 
not come to examination at the 5-year follow-up; thus 57 men were re-
examined with HRpQCT. However, due to motion artifacts, examinations of 
54 men were eligible for analyses of changes in vBMD and cortical area. 
Microarchitecture parameters are more sensitive to motion artefacts than 
vBMD and cortical area, and 45 examinations were eligible for analyses of 
changes in microarchitecture. [220] 
The patients underwent the same physical examinations at baseline and at the 
5-year follow-up performed by one physician, Eva Klingberg, at baseline and 
by me at the follow-up. Physical examinations included evaluation of 66/68 
joint count for swollen and tender joints and the Bath AS Metrology Index 
(BASMI) for evaluation of spinal and hip mobility. [37] BASMI contains 
five clinical measurements: tragus to wall distance, lumbar flexion, cervical 
rotation, lateral lumbar flexion and intermalleolar distance. BASMI ranges 
from 0-10, with 10 being the most impaired mobility. To calibrate the 
examination, BASMI was practiced together with Eva Klingberg before the 
5-year follow-up. Patients’ height and weight were measured and BMI was 
calculated. In paper II BMI was categorized in three groups: 1 = normal 
(BMI 18.5 – 24.9 kg/m2), 2 = overweight (BMI 25.0 – 29.9 kg/m2) and 3 = 
obese (BMI ≥ 30 kg/m2). [221] In paper II, patients were also categorized 
according to type of occupation; blue collar work involving manual labor and 
physical tasks and white collar work requiring less physical activity and more 
formal education. [222]  
4.2 CONTROLS 
Paper IV. Healthy controls were used for comparison of baseline s-HGF. 
Controls were recruited among blood donors at Sahlgrenska University 
Hospital while giving blood. They answered a questionnaire stating they 
were in full health and not on any medication. 
4.3 QUESTIONNAIRES 
Paper I-IV. Questionnaires included lifestyle factors, risk factors for 
osteoporosis, medical history, AS manifestations and medications. The effect 
of AS on general wellbeing was evaluated with Bath AS Patient Global score 
(BAS-G) during the last week (BAS-G1) and the last 6 months (BAS-G2). 
[223] Disease activity was evaluated with BASDAI and ASDAS_CRP. [37] 
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BASDAI includes 6 questions and the patients grade each answer from 0-10 
using a visual analogue scale. The questions include 1) the level of 
fatigue/tiredness, 2) the overall level of neck, back or hip pain, 3) the level of 
pain/swelling in other joints, 4) the level of discomfort from areas tender to 
touch or pressure, 5) the level of morning stiffness and 6) the duration of 
morning stiffness. An overall score is then calculated, ranging from 0-10. 
ADSAS_CRP is calculated by a specific formula which includes question 
number 2, 3 and 6 from BASDAI, BAS-G1 and CRP. At the 5-year follow-
up, data about NSAID consumption during the last 5 years was collected and 
quantified according to the recommendations of the ASAS recommendations. 
[224] The NSAID-index is calculated based on the type of NSAID, the dose 
and the number of days taking NSAID during the period of interest. The 
index ranges from 0-100.  
4.4 REVIEW OF MEDICAL RECORDS 
Information about the duration of treatments with TNFi and bisphosphonates 
and dose of glucocorticoids during the follow-up time was extracted from the 
medical records at the 5-year follow-up. The dose of glucocorticoids was 
converted into milligrams of prednisolone. In paper I, use of TNFi or 
bisphosphonates was calculated by dividing the number of months of 
exposure to either medication with the follow-up time in months for each 
patient, resulting in a value between 0 and 1. In paper II-IV treatment during 
follow-up time with TNFi or bisphosphonates was dichotomized in exposure 
to the treatment during follow-up or not. Additionally in paper III, patients 
were also dichotomized in having used TNFi ≥ 4 years or not during follow-
up. This was done to have a more homogenous group of patients with similar 
length of exposure to TNFi in this study with fewer participants. Of the 16 
patients exposed to TNFi during follow-up, only 4 patients had used TNFi for 
< 4 years, and had a short time of exposure of median 10.5 months. In paper 
III, the dose of prednisolone was dichotomized in having used < or ≥ 450 mg 
prednisolone during follow-up, a dose equivalent of 5 mg prednisolone/day 
during 3 months.  
4.5 BLOOD SAMPLES 
Paper I-IV. Blood samples for analyses of CRP, ESR and white blood cell 
count (WBC) were analyzed consecutively by standard laboratory techniques 
at baseline and at the 5-year follow-up. At both occasions, serum and plasma 
samples were obtained and stored, first at -20°C and then at -80°C until 
further analyses were done.  
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Time-averaged CRP and ESR for the follow-up time were calculated at the 5-
year follow-up. The first recorded CRP/ESR in the medical records each year 
was used unless the patient had an infection; in that case the subsequent test 
was used.   
Paper IV. S-HGF was analyzed using an enzyme-linked immunosorbent 
assay (ELISA) kit (Quantikine® ELISA, R&D Systems Inc., Minneapolis, 
MN, USA) according to the manufacturer´s instruction after baseline and the 
5-year follow-up. Absorbance was read at 450 nm in the spectrophotometer 
SpectraMax® 340PC384 (Molecular Devices, San Jose, CA, USA). The 
software SoftMax® Pro 5.2 (Molecular Devices) was used for calculating the 
concentration of HGF. 
4.6 RADIOGRAPHY 
Conventional radiographs of the cervical, thoracic and lumbar spine were 
obtained at baseline and at the 5-year follow-up. All radiographs were scored 
simultaneously by the same musculoskeletal radiologist blinded to the 
clinical data but with known chronological order.  
4.6.1 AS RELATED SPINAL ALTERATIONS 
Paper I-IV. AS related spinal alterations were scored according to the 
mSASSS. With mSASSS, each anterior corner of the vertebrae in cervical 
(from the lower corner of C2 to the upper corner of T1) and lumbar spine 
(from the lower corner of T12 to the upper corner of S1) is graded on lateral 
radiographs with a score between 0 and 3: 0 = normal, 1 = erosion, squaring 
or sclerosis, 2 = syndesmophyte and 3 = total bony bridging between upper 
and lower vertebral corners (ankylosis). The total score ranges from 0 to 72 
[65] (Figure 3). Spinal radiographic progression was defined as either an 
increase of ≥ 2 mSASSS over 5 years or development of ≥ 1 new 
syndesmophyte over 5 years. 
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Figure 3. With mSASSS, each anterior corner of vertebrae lower C2 to upper T1 and 
lower T12 to upper S1 are graded from 0 to 3. The total score ranges from 0 to 72 
[65] 
4.6.2 VERTEBRAL FRACTURES 
Paper I. Vertebral fractures were evaluated by the semiquantitative method 
Genant score. With Genant score, vertebrae T4 to L4 are assessed for 
reductions in height of the anterior, middle and/or posterior vertebral body. 
Each vertebra is graded 0 = normal, 1 = mild (20 - 25 % reduction in height), 
2 = moderate (26 – 40 % reduction in height) or 3 = severe (> 40 % reduction 
in height). [225] Progression in Genant score was defined as development of 
a fracture in a previously normal vertebra or worsening of at least 1 point in 
Genant score (Figure 4). 
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Figure 4. Grading of vertebral fractures according to Genant score [225] 
4.7 BONE MINERAL DENSITY 
4.7.1 DUAL ENGERGY X-RAY ABSORPTIOMETRY 
Paper I and III. With DXA, aBMD (g/cm2) was assessed at the left hip (total 
hip and femoral neck), the lumbar spine AP projection (vertebrae L1-L4) and 
lateral projection (vertebrae L2-L4), and the non-dominant forearm (total 
radius). By combining the AP and lateral projection, an estimation of lumbar 
vBMD (g/cm3) was obtained from the DXA machine. Measurements were 
done using the same DXA scanner (Hologic Discovery A, Hologic Inc., 
Bedford, MA USA) at baseline and at the 5-year follow-up.  
4.7.2 HIGH RESOLUTION PERIPHERAL QUANTITATIVE 
COMPUTED TOMOGRAPHY 
Paper III. With HRpQCT, trabecular and cortical vBMD (mg/cm3), cortical 
area (mm2) and microarchitecture (trabecular number (per mm), trabecular 
separation (mm), trabecular thickness (mm)) were assessed in the non-
dominant ultra-distal radius and tibia using the same machine at baseline and 
the 5-year follow-up (Xtreme CT, Scanco Medical AG, Brüttisellen, 
Switzerland). Trabecular and cortical vBMD, cortical area and trabecular 
number were measured directly and the other parameters were derived. [226] 
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4.8 ETHICAL CONSIDERATIONS 
All patients were exposed to radiation through the spinal radiographs and the 
DXA, with estimated effective radiation dose of 1.6 mSv for the radiographs 
and 0.025 mSv for the DXA, both at baseline and at the 5-year follow-up. 
The men that were randomized to HRpQCT also underwent QCT and had an 
additional exposure of 0.61 mSv at each occasion. For comparison, the 
approximate effective annual radiation dose in Sweden from sources like 
cosmic radiation, the ground, the body and food is 1.5 mSv 
(www.stralsakerhetsmyndigheten.se/contentassets/27621960d345484694bcd
4f0e734b4bb/200702e-radiation-environment-in-sweden-summary). All data 
were collected in a database with the personal data coded, and only 
authorized investigators had access to the database and the code. The patients 
were free to withdraw from the study at any point. Approvals of the regional 
ethics committee in Gothenburg and the local committee of radiation 
protection in Gothenburg were obtained at baseline and at the 5-year follow-
up. The study was carried out in accordance with the principles of the 
Declaration of Helsinki. All patients and healthy controls gave their informed 
written consent. 
4.9 STATISTICS 
Paper I-IV. All statistical analyses were performed using IBM SPSS 
Statistics 22 (IBM, Armonk, NY, USA), except calculation of HGF cut-off 
point in paper IV where SAS software version 9.4 (SAS, Cary, NC, USA) 
was used.  
Descriptive statistics are presented as number and percentage, mean and 
standard deviation (SD) or median and 25th (Q1) and 75th (Q3) percentile. To 
compare continuous data between different groups, the t-test was used for 
normally distributed data and the Mann Whitney U-test for variables not 
normally distributed. The Chi-square test or Fischer´s exact test were used for 
comparison of categorical variables. For repeated measurements, the paired t-
test was used for normally distributed data, the Wilcoxon signed rank test for 
not normally distributed data and McNemar´s test for categorical variables. 
Bivariate correlations were calculated using Spearman´s rank correlation (rs). 
∆-values were calculated by subtracting the baseline value from the follow-
up value. All tests were two-tailed and p ≤ 0.05 was considered statistically 
significant. 
Paper I. The one-sided t-test was used to compare the Z-score of the patients 
to the test value 0. Standard multivariable linear regression analyses were 
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conducted with ∆-BMD at the different measuring sites as a dependent 
variable. Covariates entered in the models were demographic variables 
known to affect BMD and disease related variables as well as medications 
that were hypothesized to influence ∆-BMD.  
Paper II. For calculation of reliability data, 40 randomly selected radiographs 
were re-scored by the same radiologist. Intra-reader agreement for status 
scores and change scores were assessed by an intraclass correlation 
coefficient (ICC) two-way mixed-effect model, with single measurement and 
absolute agreement. [227] The smallest detectable change (SDC) was 
calculated as proposed by Bruynesteyn et al. [228] Univariate and 
multivariable (backward method) binary logistic regression analyses were 
conducted with progression ≥ 2 mSASSS/5 years or development of ≥ 1 new 
syndesmophyte over 5 years as a dependent variable. Yes was coded 1 and no 
was coded 0. Analyses were conducted in the total group and stratified by 
sex. Covariates considered for the multivariable models were variables with 
p-value < 0.2 in the univariate analyses for the total group and p-value < 0.1 
for the sex stratified analyses. Propensity scores for the probabilities of being 
exposed to bisphosphonates, being exposed to TNFi or being treated with 
TNFi ≥ 2 years were calculated and used as a covariate together with the 
treatment variable in standard binary logistic regression analyses.  
Paper III. Univariate and standard multivariable linear regression analyses 
with ∆-cortical vBMD, ∆-trabecular vBMD or ∆-cortical area as a dependent 
variable were conducted. Covariates considered for the multivariable models 
were variables with a p-value ≤ 0.1 in the univariate analyses.  
Paper IV. The average s-HGF was calculated. For men, a receiver operating 
characteristic (ROC) curve was plotted with baseline s-HGF as the test 
variable and development of ≥ 1 new syndesmophyte over 5 years as the 
categorical state variable. Youden’s index was then used to identify an 
optimal cut-off point for a predictive s-HGF value. For the s-HGF cut-off 
point, calculations of positive (LR+) and negative (LR-) likelihood ratio for 
developing ≥ 1 new syndesmophyte were performed. Univariate binary 
logistic regression analyses with progression of ≥ 2 mSASSS over 5 years or 
development of ≥ 1 new syndesmophyte as dependent variable and baseline 
s-HGF, HGF cut-off point or the average s-HGF as a covariate were 
conducted. If the univariate p-value was ≤ 0.05, multivariable logistic 
regression analyses (backward method) were conducted and adjusted for 
covariates significant for spinal radiographic progression in paper II.  
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4.10 FOLLOW-UP AFTER THE STUDY 
The results from radiography and the DXA examinations at the 5-year 
follow-up were communicated to the patients by mail. All patients also got 
written information about life-style factors that can influence bone health. 
Patients were prescribed treatment with bisphosphonates and/or substitution 
with calcium and vitamin D according to the algorithm shown in Table 8.  
Table 8. Algorithm for prescription of bisphosphonates and/or calcium + 
vitamin D after DXA and radiography at the 5-year follow-up 
Patients were prescribed alendronate and calcium + vitamin D if:  
-Vertebral fracture on radiography or hip fracture 
-T-score < -3 SD 
-T-score ≤ -2.5 SD and 1 major or 2 minor risk factors 
 Major risk factors  Minor risk factors  
 -Previous low-energy fracture 
in wrist, upper arm, pelvis (VF 
and hip fracture) 
-Treatment with prednisolone 
 -Age of menopause before 
45 years old 
-Smoking 
-Inactivity 
 
   >3 months 
-Hip fracture or VF in parent 
 -BMI < 20 kg/m2 
-High risk of falling 
 
     
-T-score ≤ - 2 SD and > - 2.5 SD + FRAX® ≥ 15 % + previous fracture 
-T-score < -1 SD + Prednisolone 
Patients were prescribed calcium + vitamin D in monotherapy if:  
Normal BMD  + Prednisolone 
Decision was based on BMD at femoral neck, total hip and lumbar spine AP.   
FRAX®; Fracture Risk Assessment Tool 
 
Treatment with bisphosphonates and calcium + vitamin D was prescribed to 
17 patients, 9 women and 8 men, with median (Q1, Q3) age of 64 (54.5, 72) 
years old. All women except one were menopausal at the 5-year follow-up. 
Monotherapy with calcium + vitamin D was not initiated in anyone. 
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5 RESULTS AND DISCUSSION 
5.1 PAPER I 
Which measuring site in ankylosing spondylitis is best to detect bone loss 
and what predicts the decline: results from a 5-year prospective study. 
In this study we investigated how BMD changed over five years in patients 
with AS and factors associated with the changes. Several measuring sites 
were assessed: the total hip, the femoral neck, the total radius and the spine, 
both AP and lateral projection. For the first time, the lateral projection of the 
spine was assessed longitudinally in patients with AS. There were 168 
patients that were examined at both baseline and at the 5-year follow-up, 92 
men and 76 women. At baseline, the mean (SD) age was 50 (13) years old 
and the mean (SD) symptom duration was 24 (13) years.  
5.1.1 MAIN RESULTS 
• BMD decreased significantly at the femoral neck and total 
radius. 
• BMD increased significantly at the total hip and the lumbar 
spine, both the AP and lateral projections. 
• Elevated time-averaged CRP was associated with decreases 
in femoral neck BMD. 
• Use of bisphosphonates was associated with increases in 
BMD at all sites except total radius. 
• Use of TNFi was associated with increases in AP spine 
BMD. 
5.1.2 CONCLUSION 
This longitudinal study that assessed changes in BMD at five different 
measuring sites including the lateral spine, suggests that the best 
measurement site for assessment of bone loss over time in patients with long 
standing AS is at the femoral neck. This study also suggest that systemic 
inflammation has a negative effect on BMD at all measured sites except total 
radius and that use of bisphosphonates and TNFi has a positive effect on 
BMD in patients with AS.   
5.1.3 DISCUSSION 
BMD and T-score decreased during follow-up at the femoral neck, in both 
sexes, and persistent elevated CRP was independently associated with the 
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decreases. These findings are in line with some previous studies on patients 
without TNFi. In patients with early AS or IBP, decreases in femoral neck 
BMD were found to be more pronounced in patients with persistent systemic 
inflammation, [194] or decreases only found in patients with active disease. 
[193, 195] One study found no significant change in femoral neck BMD 
regardless of disease activity. [197] Also in an older patient group, all with 
active disease and low BMD at baseline, femoral neck decreased. [204] The 
patients in these studies were younger than in the current study, and we found 
older age to be an independent predictor of femoral neck bone loss in this 
current cohort. Also, in comparison with the reference population, the 
femoral neck BMD in the current study did not differ significantly from the 
age and sex-matched controls. However, if age was excluded from the 
multivariable regression model and the change in adjusted R2 was assessed, 
age explained a rather small part of 4 % of the variation in ∆-BMD. Use of 
bisphosphonates but not TNFi was independently associated with increases in 
femoral neck BMD. The effect of TNFi on femoral neck BMD is not so well 
studied, and previous studies have shown increases in BMD [204] as well as 
no significant change. [229]  
The AS patients also decreased in BMD and T-score at the total radius. 
However, the only variable found to be independently associated with 
changes in BMD was older age. Also, compared to the age- and sex-matched 
reference values, the patients differed in BMD neither at baseline nor at the 
follow-up. Hence, the decreases in BMD at radius do not seem to be related 
to the disease.  
In contrast to femoral neck and total radius, BMD at the total hip and lumbar 
spine AP and lateral projection increased. In sex stratified analyses, 
significant increases were found in men, and male sex was independently 
predicting increases in BMD at the total hip with a trend at the AP spine. 
However, in sex stratified analyses, men and women with AS did not differ 
in BMD at baseline compared to the age- and sex-matched reference group, 
whereas BMD at the follow-up at the total hip and AP spine were higher in 
the AS patients. This would imply an increase in BMD or less bone loss than 
in the general population for both sexes. Reference values for the lateral 
projection were only available for women and women with AS showed 
higher lateral BMD than the reference population at the follow-up also at this 
site.  
Increasing ESR from baseline to follow-up was associated with decreases in 
BMD at the total hip, spine AP and lateral spine, whereas use of 
bisphosphonates were independently associated with increases. Use of TNFi 
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was independently associated with increases in AP spine BMD. When 
patients with bisphosphonates and TNFi were excluded from analyses, BMD 
did not change significantly at these sites and high time-averaged ESR was 
associated with decreases in BMD, except at AP spine. Previous reports on 
changes in BMD in AS patients without treatment with bisphosphonates and 
TNFi are not consistent. BMD at the spine AP has been shown to be stable, 
[194, 195] to increase, [196, 197] and also to decrease in patients with active 
disease. [193] Methods for evaluation of AS related spinal alterations differed 
between the studies and this parameter is difficult to compare between the 
studies. Changes previously reported for total hip BMD are decreases in 
patients with active disease, [195] and high ESR during follow-up was shown 
to be associated with decreases in total hip BMD and also AP spine BMD in 
another cohort. [196] To further analyze the impact of bisphosphonates and 
TNFi on the increases in BMD at the spine and total hip in the current cohort, 
the treatments were removed from the multivariable regression models, and 
the change in adjusted R2 was assessed. For the total hip and the lateral spine, 
bisphosphonates and TNFi together explained 10 % of the variation in ∆-
BMD, and for the AP spine it was as much as 20 % (data not in the article). 
These treatments have an impact, but other factors are also contributing to the 
changes in BMD. No independent association between AS related alterations 
in the spine and changes in spinal BMD were found.  
The AP spine was the site with the highest adjusted R2, with 44 % of the 
variation in ∆-BMD explained by the independent variables. Hence, many 
factors associated with changes in BMD were not identified in this current 
study. There are factors not included in the regression models that can affect 
BMD, such as use of proton pump inhibitors, selective serotonin reuptake 
inhibitors, anti-diabetics, alcohol abuse, and serum levels of vitamin D, 
calcium or parathyroid hormone. However, the number of participants in the 
study restricted the number of variables possible in the multivariate 
regression models.  
Prevalences of osteoporosis did not change significantly between baseline 
and the 5-year follow-up. If patients with osteoporosis/BMD below expected 
range for age at baseline were excluded, 12 of 129 patients were found to 
develop osteoporosis/BMD below expected range for age during follow-up. 
All had osteopenia at baseline, but patients were too few for analyses of 
independent predictors for development of osteoporosis. The measured sites 
with newly developed osteoporosis were femoral neck (n = 5), radius (n=4), 
AP spine (n=3) and lateral spine (n=1). Of the 39 patients with 
osteoporosis/BMD below expected range for age at baseline, 6 patients did 
not have osteoporosis any longer at the 5-year follow-up. All 6 patients had 
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been exposed to bisphosphonates, and one patient was exposed to TNFi 
during follow-up (data not in article).  
Very few patients developed VFs during follow-up; only 3 patients (1.8 %) 
developed new VFs of which one patient also worsened in previous VFs. 
Despite treatment with TNFi and increases in BMD, previous studies have 
reported AS patients to continue to develop new VFs in up to 20 % of the 
participants. [199, 203, 205] We can only speculate if the low occurrence of 
new VFs in patients in this current cohort is related to initiation of 
bisphosphonates after the baseline measurements in patients at higher risk of 
developing VFs.  
5.2 PAPER II 
A five-year prospective study of spinal radiographic progression and its 
predictors in men and women with ankylosing spondylitis. 
In this study we assessed spinal radiographic progression over five years and 
predictors for the progression in the total group and in men and women 
separately. Definite spinal radiographic progression was defined as either 
progression of ≥ 2 mSASSS/5 years or development of ≥ 1 new 
syndesmophyte/5 years. There were 166 patients examined at baseline and at 
the 5-year follow-up who also had a baseline mSASSS < 72.  
5.2.1 MAIN RESULTS 
• The total group had a progression of mean (SD) 1.6 (3.3) 
mSASSS over five years (p<0.001), 47 patients (28 %) had a 
progression of ≥ 2 mSASSS/5 years and 36 patients (22 %) 
developed ≥ 1 new syndesmophyte.  
• Men increased more in mSASSS compared to women, and 
more men than women had a progression of ≥ 2 mSASSS 
and development of ≥ 1 new syndesmophyte.  
• In the total group, radiographic progression was associated 
with baseline syndesmophytes, elevated baseline CRP, male 
sex, older age, obesity and exposure to bisphosphonates 
during follow-up.  
• Factors associated with radiographic progression only found 
in men were elevated baseline CRP and smoking.  
• Factors associated with radiographic progression only found 
in women were exposure to bisphosphonates during follow-
up and a high BASMI.  
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5.2.2 CONCLUSION 
Over five years, men had more radiographic progression than women. The 
study suggests that predictors for spinal radiographic progression may partly 
differ between sexes. New predictors identified in this study were obesity in 
both sexes and impaired spinal mobility and exposure to bisphosphonates 
during follow-up in women. Among previously known predictors, baseline 
AS related spinal alterations was shared by sexes whereas elevated baseline 
CRP and smoking were predictors in men. The role of bisphosphonates in 
spinal radiographic progression needs to be further studied.  
5.2.3 DISCUSSION 
Men had higher baseline mSASSS and higher progression of mSASSS than 
women, more men had definite radiographic progression compared to women 
and male sex was an independent predictor for progression of ≥ 2 mSASSS in 
this current study. Previous studies have also reported more AS related spinal 
alterations in men [72-74], faster progression and more men with 
development of new syndesmophytes compared to women [67, 74] and male 
sex to predict spinal radiographic progression. [69, 143] The reason for this 
difference is not known. Reports on disease related sex-differences are scarce 
and knowledge about underlying mechanisms for spinal radiographic 
progression is limited. This current study is the first to report factors 
associated with spinal radiographic progression in sex stratified analyses, 
except Hartl et al who studied biomarkers stratified by sex and reported low 
leptin and HMW-APN to predict radiographic progression in men. [113]. We 
had a rather even distribution of men and women in the current cohort. 
However, women had a low frequency of definite spinal radiographic 
progression which reduced the statistical power in the sex stratified analyses 
which need to be interpreted with caution and is a limitation with the study. 
Nevertheless, our results suggest that smoking has a negative effect on spinal 
radiographic progression in men only. Elevated CRP was a significant 
predictor in men, but showed a trend in women, so the sex difference might 
be related to few women with definite radiographic progression. Both 
elevated CRP and smoking have been shown to predict radiographic 
progression in several previous studies. [68, 99, 100, 140]  
Obesity was associated with radiographic progression in both sexes. One 
previous study has reported overweight and obese patients to have higher 
baseline mSASSS compared to normal weight patients, and high BMI and 
BMI ≥ 25 kg/m2 were predictors of spinal radiographic progression in 
univariate analyses. However, no independent association was found in that 
study. [70]  In a retrospective study published as a letter (with some important 
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information on methodology lacking) some type of time-averaged BMI ≥ 25 
kg/m2 was independently associated with spinal radiographic progression, 
[230] whereas Molnar et al found no association between baseline BMI 
categories and radiographic progression. [69] There are several possible 
mechanisms for obesity being associated with spinal radiographic 
progression. It could be related to increased mechanical stress as new bone 
formation has been shown to be associated with mechanical loading in a 
mouse model of SpA, [88] and indirectly with blue collar work. [92] It could 
also be related to adipose tissue being an endocrine organ with production of 
adipokines, [231] and elevated level of the adipokine serum visfatin has been 
shown to independently predict spinal radiographic progression. [112] 
Additionally, obesity has been shown to be independently associated with 
higher disease activity and worse physical function in patients with axial SpA 
[232] and AS patients with overweight and obesity had a more negative 
perception of benefits of exercise compared to those with normal BMI. [233] 
Also, overweight and obese axial-SpA patients had worse treatment response 
to TNFi compared to patients with normal BMI. [234, 235] 
Exposure to bisphosphonates during follow-up was found to be associated 
with radiographic progression in women. This novel finding is intriguing, and 
has resulted in a letter by Orsolini et al. [236] They hypothesized that the 
association found was due to more severe bone loss in patients with 
radiographic progression. This hypothesis is plausible. Kim et al. recently 
reported low BMD at any measured site (spine AP, total hip and femoral 
neck) to be an independent predictor for spinal radiographic progression in 
patients with axial SpA. [140] A very recent publication reported low BMD 
at the lateral spine to be an independent predictor of radiographic 
progression. [237] Analyses in our current study show no univariate 
association with radiographic progression for baseline BMD (AP, lateral, 
total hip, femoral neck and total radius) or baseline osteoporosis/BMD below 
expected range for age at any measured site (data not in article). 
Mechanistically, bisphosphonates bind to hydroxyl apatite crystals in the 
skeleton, especially at sites with high bone turnover. They mainly have an 
anti-resorptive effect and inhibit the osteoclasts maturation, proliferation and 
activity and promote apoptosis of the osteoclasts. Bisphosphonates are also 
suggested to have a direct positive effect on osteoblasts but this role is less 
clear. [238] Results from experiments on the effect of bisphosphonates on 
osteoblasts are contrasting, but overall, the observations suggest that 
bisphosphonates promote bone formation. [239] Bisphosphonates also have 
an anti-inflammatory effect. [240] Open-label studies on patients with SpA 
have shown an effect on both peripheral and axial disease with the 
intravenously administered bisphosphonate pamidronate, [241] whereas 
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orally administered alendronate did not have such an effect in a randomized, 
placebo controlled study. [242] The role of bisphosphonates in spinal 
radiographic progression needs indeed to be further investigated since it is an 
important medication for osteoporosis and prevention of fractures.  
5.3 PAPER III 
Factors associated with changes in volumetric bone mineral density and 
cortical area in men with ankylosing spondylitis. A five-year prospective 
study using HRpQCT.  
In this study we assessed changes in cortical and trabecular vBMD, cortical 
area and microarchitecture over five years and factors associated with the 
changes in vBMD and cortical area using HRpQCT at the ultra-distal radius 
and tibia. Of the 69 men randomized to the examinations at baseline, 54 men 
had assessable examinations for analyses of vBMD and cortical area both at 
baseline and at the follow-up, whereas 45 men had assessable examination 
for analyses of microarchitecture. At baseline, the mean (SD) age was 48 (14) 
years old and the mean (SD) symptom duration was 22.5 (13) years.  
5.3.1 MAIN RESULTS 
• Cortical and trabecular vBMD at tibia decreased more than 
the least significant change (LSC). 
• Worsening of the microarchitecture at tibia was found, but 
changes did not exceed LSC.  
• An increase in ASDAS_CRP from baseline to follow-up 
was independently associated with decreases in cortical 
vBMD and cortical area at tibia. 
• High time-averaged ESR was associated with decreases in 
cortical area at radius. 
• Use of TNFi ≥ 4 years during follow-up was associated with 
increases in cortical vBMD and cortical area at tibia. 
• Exposure to bisphosphonates during follow-up was 
associated with increases in cortical vBMD and cortical area 
at radius.  
5.3.2 CONCLUSION 
Over five years, the men with AS decreased significantly in cortical and 
trabecular vBMD at tibia. Disease related factors and medications were found 
to affect cortical bone. Signs of active inflammation were associated with 
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decreases in cortical parameters whereas treatment with TNFi and 
bisphosphonates were associated with increases in cortical bone.  
5.3.3 DISCUSSION 
This is to our knowledge the first longitudinal study on patients with AS or 
nr-axial SpA using HRpQCT. We found decreases in trabecular vBMD and 
cortical vBMD that exceeded LSC (change judged as “true” change with 95 
% confidence, the change exceeding the precision error of the method) at 
tibia. The precision error was larger for the assessments of microarchitecture 
(trabecular thickness, trabecular separation and trabecular number) and the 
deterioration found in microarchitecture did not exceed LSC.  
One of the limitations with the method is that there are no reference values 
for HRpQCT measurements to compare our results to. Previous cross-
sectional studies on patients with AS or nr-axial SpA have compared 
measurements between patients and controls. Two studies included both 
sexes and showed patients to have impaired measurements compared to 
controls in cortical bone, with decreased cortical vBMD at both tibia and 
radius [243] and decreased cortical vBMD, area and thickness at radius (tibia 
not measured). [244] The baseline study on our cohort with men showed 
decreased cortical vBMD at tibia and decreased trabecular vBMD at radius 
compared to controls, [245] whereas Caparbo et al. reported decreased 
trabecular parameters (vBMD, thickness and separation) at tibia in men with 
AS. [246]  
We have no control group for the longitudinal assessments, which is a 
limitation. There are two longitudinal studies using HRpQCT on general 
population that we can use for indirect comparison. In relation to these 
studies, our patients deteriorate in cortical vBMD at tibia at earlier age than 
men in the general population, whereas decrease in trabecular vBMD did not 
occur in the men in the general population in any age group. [247, 248] 
Regression analyses regarding factors associated with changes in HRpQCT 
measurements were conducted for changes in cortical and trabecular vBMD 
and cortical area. Factors associated with changes in microarchitecture were 
not analyzed based on the large precision errors for these measurements and 
because of less assessable examinations (n = 45). In regression analyses, 
factors associated with changes in HRpQCT parameters were mainly 
identified for cortical vBMD and cortical area. For tibia, an increase in 
disease activity from baseline to follow-up was negative for bone health and 
for radius, high time-averaged ESR was negative. One of the cross sectional 
studies using HRpQCT in this patient group analyzed the association between 
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disease activity or markers of inflammation and HRpQCT parameters. They 
found a negative correlation between ESR and cortical and trabecular vBMD 
and cortical thickness at tibia. [243] Negative impact on changes in aBMD in 
this patient group by inflammation has been found in several longitudinal 
studies both at the femoral neck and spine AP. [193, 194, 196]  
Exposure to TNFi during follow-up was not significantly associated with 
changes in HRpQCT parameters. However, four patients had a short 
exposure time (median 10.5 months) to TNFi. Since there were relatively few 
patients in the study, patients with longer TNFi treatment (≥ 4 years) were 
analyzed for associations with changes in HRpQCT parameters. This longer 
exposure to TNFi was associated with increases in cortical parameters at 
tibia, in line with the previously mentioned association with TNFi treatment 
and increases in aBMD at the femoral neck and spine. Relatively few patients 
were exposed to bisphosphonates during follow-up (13 %) and fewer patients 
were exposed to a systemic dose of prednisolone ≥ 450 mg during follow-up 
(7 %). Both medications are important factors for BMD and were therefore 
included in the analyses. Exposure to bisphosphonates was associated with 
increases in cortical parameters at radius and prednisolone was associated 
with decreases in cortical parameters at tibia. Why treatments did not affect 
both radius and tibia could not be elucidated, but could be related to the small 
sample size and few exposed patients.  
Hardly any factors related to changes in trabecular vBMD were found. At 
tibia, only younger age was associated with decreases in trabecular vBMD, 
and decreases were especially found in patients < 40 years old at baseline. 
Further analyses could not elucidate the reason for this unexpected 
relationship.  
Do HRpQCT parameters have any clinical implications? Fracture prediction 
by aBMD measured by DXA has limitations, and a large proportion of 
fractures occur in patients with T-score > - 2.5 SD, in men in a larger 
proportion than in women. [249] Prospective studies on incident fractures in 
older men using HRpQCT have shown an additive value for fracture 
prediction by these measurements. After adjustment of aBMD (among other 
things) incident fractures were significantly associated with decreased 
cortical parameters and trabecular bone mass at tibia [250], decreased cortical 
and trabecular vBMD at tibia and radius [251] and decreased trabecular 
vBMD, number and separation at radius. [252] There are no studies on 
changes in HRpQCT measurements over time and fracture risk.  
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5.4 PAPER IV 
Elevated serum level of hepatocyte growth factor predicts development 
of new syndesmophytes in men with ankylosing spondylitis. Results from 
a five-year prospective study.  
In this study we investigated if baseline s-HGF and the average s-HGF were 
associated with spinal radiographic progression in patients with AS overall 
and by sex. We also analyzed factors correlated to changes in s-HGF between 
baseline and follow-up. This is the first longitudinal study assessing s-HGF 
as a predictor of spinal radiographic progression. There were 163 patients 
with radiographs and s-HGF at both baseline and the 5-year follow-up who 
also had a baseline mSASSS < 72.  
5.4.1 MAIN RESULTS 
• Baseline s-HGF and the average s-HGF were significantly 
higher in men with spinal radiographic progression 
compared to men without progression. This difference was 
not found in women. 
• Baseline s-HGF and the average s-HGF did not differ 
between men and women with AS.  
• An optimal cut-off point for baseline s-HGF for the 
prediction of development of ≥ 1 new syndesmophyte was 
calculated for men; in the ROC analysis, the area under the 
curve (AUC) was 0.70. 
• Baseline s-HGF, the optimal cut-off point and the average s-
HGF were all independent predictors of spinal radiographic 
progression in men.  
• Changes in s-HGF were positively correlated to changes in 
ESR and CRP.  
5.4.2 CONCLUSION 
Elevated s-HGF is an independent predictor of spinal radiographic 
progression in men with AS. The predictive ability is modest. Whether the 
predictive ability can be improved by adding other biomarkers or clinical 
parameters is not known.  
5.4.3 DISCUSSION 
In the baseline, cross-sectional report on this cohort, elevated s-HGF was 
found to be independently associated with higher mSASSS, so in this study 
we aimed to assess if s-HGF also was related to spinal radiographic 
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progression. The analyses showed baseline s-HGF, s-HGF ≥ cut-off point and 
the average s-HGF to independently predict development of ≥ 1 new 
syndesmophyte in men with AS. Supporting the role of a prognostic 
biomarker for radiographic progression is the correlation between other 
variables previously identified as predictors, such as elevated CRP, smoking 
and high BMI. Besides a study showing an association between s-HGF and 
elevated CRP and BASDAI in patients with AS, [114] no other findings on s-
HGF and AS are reported. The role of HGF in other rheumatic diseases is not 
clear, as previously mentioned, and studies are limited.  
Possible mechanisms for HGF in relation to spinal radiographic progression 
include promotion of osteogenesis by an effect on bone cells or by an 
angiogenetic effect, [137, 253] or by HGF having an effect on the disease by 
the immune system. [123] Or, elevated HGF could be a response to 
inflammatory cytokines [129] with no direct mechanism on the disease.  
The AUC of 0.70 for prediction of ≥ 1 new syndesmophyte in men in this 
current study was similar to the AUC reported in other studies on biomarkers 
for the prediction on spinal radiographic progression in AS and nr-axial SpA. 
The AUC previously reported ranged from 0.65 to 0.74 for elevated levels of 
biomarkers like VEGF, MMP3, s-Calprotectin and visfatin, [104, 106, 107, 
112] and lower levels of leptin. [113] Even though elevated citrullinated and 
matrix metalloproteinase-degraded fragment of vimentin (VICM) was 
independently associated with radiographic progression, the AUC was only 
0.59. [254] Lower level of HMW-APN showed an AUC of 0.62. [113] The 
predictive value for studied biomarkers are moderate, and as previously 
mentioned, not consistent in different cohorts. The most recent study on 
biomarkers published in this patient group added clinical parameters to a 
combination of biomarkers and some improvement of the prediction was 
found; the AUC for VEGF, leptin and HMW-APN together increased from 
0.73 to 0.77 with clinical parameters. [109] Whether the prediction of spinal 
radiographic progression can be improved if HGF is combined with other 
biomarkers or with clinical parameters remains to be investigated.  
S-HGF decreased over five years in the patients with AS. The decrease was 
associated with decreases in inflammatory parameters. No treatments were 
correlated with the changes. The effect of different treatments on changes in 
HGF can´t be evaluated properly though, since the interval between the 
measurements are too long and patients started treatments at various starting 
points. The natural fluctuation of HGF over time is not known in patients 
with AS. The handling of the blood samples in this current cohort followed a 
defined protocol used for all patients and controls. Blood samples were stored 
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at -80°C and were not thawed and re-frozen repeatedly. The same protocol 
for analyses from the manufacturer was used and followed carefully at 
baseline and the 5-year follow-up. The manufacturer reports no changes in 
the ELISA kit between baseline and follow-up analyses. All s-HGF values 
were within the standard curve. One difference between serum samples from 
baseline and the 5-year follow-up was the time in the freezer and the analyte 
can be degraded over time. However, the baseline serum samples were stored 
in the freezer for approximately 10 months longer than the follow-up samples 
before analyses were performed and thus one would expect the baseline 
samples to be lower than the follow-up values if degradation was an issue. 
Hence, no specific explanation for the decreases in s-HGF over time can be 
found.  
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6  CONCLUDING DISCUSSION AND 
FUTURE PERSPECTIVES 
Skeletal involvement in AS is complex. Both bone formation and bone loss 
are associated with the disease. Both processes contribute to the burden of the 
disease with impairment of mobility and function and an increased risk of 
vertebral fractures with the risk of neurological complications in an 
ankylosed spine. [16, 17, 214, 255] Knowledge about underlying 
mechanisms for bone loss and new bone formation is limited and it is of 
importance to gain further knowledge in this area to find modifiable factors 
in order to improve the care and the outcome for the patients with AS.  
Taking the results from the studies in this thesis together, BMD at the 
femoral neck as well as the distal tibia decreased and mSASSS increased. 
Both processes were negatively affected by signs of inflammation. This 
supports the negative relationship between inflammation and both bone loss 
and spinal new bone formation, also in patients with longstanding disease and 
that control of inflammation is an important target.  
How bone loss and new bone formation affect each other is less clear. 
Previous longitudinal studies have assessed changes in AS related spinal 
alterations in relation to changes in aBMD [197-200] in the spine and one 
study found an independent association; increases in SASSS was associated 
with increases in AP aBMD. [201] In Paper I, baseline mSASSS was 
investigated as a predictor for changes in aBMD; low mSASSS predicted 
decreases in femoral neck BMD. No independent association was found for 
spinal BMD and mSASSS or lumbar mSASSS. What would the results be if 
changes in mSASSS over 5 years were used instead? This was not analyzed 
in Paper I, however, ∆-mSASSS or radiographic progression by the two 
definitions are not associated with changes in aBMD in univariate analyses, 
and no further analyses regarding DXA measurements and mSASSS are 
planned. With QCT of the spine, trabecular and cortical vBMD can be 
separated, which is helpful in the spine with syndesmophytes. One small 
study with 15 AS patients investigated longitudinal analyses of 
syndesmophytes as predictors for changes in vBMD measured by QCT. They 
found AP BMD to increase and QCT vBMD to decrease. QCT vBMD was 
lower in patients with more advanced radiographic findings, but baseline 
syndesmophyte score by Devogelaer did not independently predict changes in 
vBMD. [189] Analyses in the study are hampered by a low number of 
participants and it would be of interest to further study factors associated with 
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changes in QCT vBMD in a larger cohort and with a validated scoring 
method for AS related spinal alterations. We have not been able to analyze 
our longitudinal QCT data yet due to technical issues.  
What about low BMD as a predictor for spinal radiographic progression as a 
proposed mechanism for AS related spinal alterations? Just recently, two 
longitudinal studies reported low BMD to be a possible predictor for spinal 
radiographic progression. [140, 237] Data from our cohort regarding this 
question has not been published. So far, we have found no association 
between aBMD and spinal radiographic progression. However, analyses of 
baseline QCT vBMD as a predictor of spinal radiographic progression are not 
conducted; this can be done and such analyses could increase the knowledge 
about the relationship between trabecular BMD and spinal new bone 
formation.  
Is mSASSS a method sensitive enough to detect relevant changes in AS 
related spinal alterations? Of the scoring methods using conventional X-ray, 
mSASSS is the method most sensitive to change, [62] and the scoring 
method still recommended in clinical trials. [63, 64] However, assessment of 
syndesmophyte growth by CT is more sensitive to change than radiography. 
[256] Recently, a new scoring method that uses low-dose CT was developed, 
the CT Syndesmophyte Score (CTSS). CTSS has the ability to reliably assess 
the thoracic spine in addition to cervical and lumbar spine. [257] With CTSS 
more spinal new bone formation was detected compared to mSASSS. Most 
progression was detected in the thoracic spine, but CTSS also detected more 
new syndesmophytes and especially more growth of syndesmophytes in the 
cervical and lumbar spine compared to mSASSS. [258] In future studies it 
would be of interest to evaluate factors associated with progression of spinal 
new bone formation using CTSS to investigate if further modifiable factors 
can be detected and to better evaluate the effect of treatments on progression.  
Use of bisphosphonates was found to have a positive impact on changes in 
BMD, whereas a negative impact was found for radiographic progression. 
However, the number of patients using bisphosphonates in this study is too 
small to draw any definitive conclusions about the negative impact. A larger 
cohort with more patients using bisphosphonates would be needed to increase 
the power of the calculations. Collaboration with other research groups that 
have included AS patients using bisphosphonates in longitudinal studies 
could be a possible approach. The same applies to further studies on sex 
differences in predictors for radiographic progression.  
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In this current cohort, the association between s-HGF and AS related spinal 
alteration was investigated for the first time. The mechanism and the relative 
importance for this association are not known. In further studies, s-HGF 
could be assessed in combination with other biomarkers and also with 
clinical predictors to analyze if the predictive value can be improved. Also, 
the effect of treatment on changes in s-HGF and its association with 
radiographic progression would be of interest to study in a larger cohort.   
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7 CONCLUSION 
The studies in this thesis suggest that the best site to assess bone loss in 
patients with longstanding AS is at the femoral neck and that inflammation 
has a negative impact on bone loss and development of AS related spinal 
alterations and thus is an important treatment target. The studies give further 
reasons to counsel the patients to stop smoking and to encourage obese 
patients to weight loss. Treatments with bisphosphonates and TNFi had a 
positive impact on BMD. Further studies are suggested regarding the role of 
bisphosphonates in relation to spinal radiographic progression and whether s-
HGF can be useful as a predictor for spinal radiographic progression.  
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